ESSA Pharma (EPIX) 10-K 18 Nov 21 2021 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Nov. 18, 2021	Mar. 31, 2021
Document and Entity Information [Abstract]
Document Type	10-K
Entity Registrant Name	ESSA Pharma Inc.
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2021
Entity File Number	001-37410
Entity Incorporation, State or Country Code	A1
Entity Address, Country	CA
Entity Tax Identification Number	47-2569713
Entity Address, Address Line One	Suite 720
Entity Address, Address Line Two	999 West Broadway
Entity Address, City or Town	Vancouver
Entity Address State Or Province	BC
Entity Address, Postal Zip Code	V5Z 1K5
City Area Code	778
Local Phone Number	331-0962
Title of 12(b) Security	Common Shares
Trading Symbol	EPIX
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
ICFR Auditor Attestation Flag	true
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Central Index Key	0001633932
Current Fiscal Year End Date	--09-30
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Public Float			$ 915.9
Entity Common Stock, Shares Outstanding		43,984,346

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2021	Sep. 30, 2020
ASSETS, Current
Cash and cash equivalents	$ 137,825,024	$ 56,320,763
Short-term investments (Note 5)	57,102,159	22,011,337
Receivables	489,012	309,538
Prepaids (Note 6)	2,181,882	1,600,128
Operating lease right-of-use assets (Note 8)	0	55,162
Total current assets	197,598,077	80,296,928
Deposits	259,455	277,637
Operating lease right-of-use assets (Note 8)	308,286	0
Total assets	198,165,818	80,574,565
LIABILITIES, Current
Accounts payable and accrued liabilities (Note 7)	3,808,944	1,144,230
Current portion of operating lease liabilities (Note 8)	120,719	59,094
Total current liabilities	3,929,663	1,203,324
Derivative liabilities (Note 10)	20,352	127,376
Operating lease liabilities (Note 8)	210,251	0
Total liabilities	4,160,266	1,330,700
Shareholders' equity
Common shares 43,984,346 issued and outstanding (September 30, 2020 - 32,064,411) (Note 11)	277,415,176	131,086,364
Additional paid-in capital (Note 11)	36,442,620	31,204,284
Accumulated other comprehensive loss	(2,076,479)	(2,076,479)
Accumulated deficit	(117,775,765)	(80,970,304)
Total stockholders equity	194,005,552	79,243,865
Total liabilities and shareholders' equity	$ 198,165,818	$ 80,574,565

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - shares	Sep. 30, 2021	Sep. 30, 2020
CONSOLIDATED BALANCE SHEETS
Common stock, shares issued	43,984,346	32,064,411
Common stock, shares outstanding	43,984,346	32,064,411

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
OPERATING EXPENSES
Research and development	$ 24,258,989	$ 12,145,968	$ 6,696,234
Financing costs (Notes 8 and 9)	22,220	618,109	602,744
General and administration	12,884,581	11,373,952	5,455,189
Total operating expenses	(37,165,790)	(24,138,029)	(12,754,167)
Foreign exchange	(16,041)	(44,851)	7,845
Interest income	234,997	559,719	26,251
Derivative liability gain (loss) (Note 10)	107,024	(110,856)	1,159
Loss for the year before taxes	(36,839,810)	(23,734,017)	(12,718,912)
Income tax recovery (expense) (Note 14)	34,349	288,647	(37,920)
Loss and comprehensive loss for the year	$ (36,805,461)	$ (23,445,370)	$ (12,756,832)
Basic and diluted loss per common share	$ (0.96)	$ (1.04)	$ (1.51)
Weighted average number of common shares outstanding - basic and diluted	38,480,378	22,443,893	8,433,441

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Loss for the year	$ (36,805,461)	$ (23,445,370)	$ (12,756,832)
Items not affecting cash and cash equivalents:
Amortization of right-of-use asset	109,464	110,324	0
Accretion of lease liability	9,570	12,992	0
Derivative liability loss	(107,024)	110,856	(1,159)
Income tax recovery	0	(280,000)	0
Interest income	(76,056)	0	0
Finance expense	31,192	211,079	602,744
Unrealized foreign exchange	0	13,059	16,457
Share-based payments	9,476,113	7,522,608	1,146,707
Changes in non-cash working capital items:
Receivables	(157,575)	89,938	(59,665)
Prepaids	(563,572)	(1,262,280)	(179,416)
Accounts payable and accrued liabilities	2,667,738	(46,358)	(1,014,049)
Income tax payable	0	(20,000)	(4,722)
Net cash used in operating activities	(25,415,611)	(16,983,152)	(12,249,935)
CASH FLOWS FROM INVESTING ACTIVITIES
Deposits	0	274,085	201,399
Purchase of short-term investments	(57,026,103)	(22,011,337)	0
Proceeds from short-term investments sold	22,000,000	0	0
Interest from short-term investments	11,337	0	0
Net cash (used in) provided by investing activities	(35,014,766)	(21,737,252)	201,399
CASH FLOWS FROM FINANCING ACTIVITIES
Cash acquired on acquisition of Realm	0	0	22,244,248
Transaction costs on acquisition of Realm	0	(64,804)	(1,860,341)
Termination costs on Realm sublease	0	0	(246,906)
Proceeds on issuance of common shares	149,999,985	48,990,000	36,000,000
Share issuance costs	(9,229,450)	(3,447,954)	(2,362,329)
Options exercised	1,186,833	915	0
Warrants exercised	596	257,172	0
Shares purchased through employee share purchase plan	133,071	80,714	0
Lease payments	(100,282)	(119,384)	0
Loan principal repaid	0	(3,199,799)	(2,808,823)
Loan final payment paid	0	(688,000)	0
Interest and financing costs paid	0	(32,235)	(401,929)
Net cash provided by financing activities	141,990,753	41,776,625	50,563,920
Effect of foreign exchange on cash and cash equivalents	(56,115)	(58,181)	(21,805)
Change in cash and cash equivalents for the year	81,504,261	2,998,040	38,493,579
Cash and cash equivalents, beginning of year	56,320,763	53,322,723	14,829,144
Cash and cash equivalents, end of year	$ 137,825,024	$ 56,320,763	$ 53,322,723

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)	Common Shares [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Retained Earnings (Deficit) [Member]	Total
Beginning Balance at Sep. 30, 2018	$ 40,205,997	$ 15,573,597	$ (2,076,479)	$ (44,768,102)	$ 8,935,013
Beginning Balance, in shares at Sep. 30, 2018	5,776,098
Acquisition of Realm	$ 20,247,296				20,247,296
Acquisition of Realm, in shares	6,718,150
Share issuance costs	$ (2,826,443)	(1,764,982)			(4,591,425)
Financing	$ 12,161,192	23,838,808			36,000,000
Financing , in shares	6,080,596
Pre-funded warrants exercised	$ 8,757,066	(8,755,996)			1,070
Pre-funded warrants exercised, shares	2,187,530
Share-based payments		1,146,707			1,146,707
Loss for the year				(12,756,832)	(12,756,832)
Ending Balance at Sep. 30, 2019	$ 78,545,108	30,038,134	(2,076,479)	(57,524,934)	48,981,829
Ending Balance, in shares at Sep. 30, 2019	20,762,374
Share issuance costs	$ (3,136,949)	(7,054)			(3,144,003)
Warrants exercised	$ 6,549,631	(6,292,459)			257,172
Warrants exercised, in shares	3,120,115
Financing	$ 48,990,000				48,990,000
Financing , in shares	8,165,000
Options exercised	$ 1,648	(733)			$ 915
Options exercised, shares	416				416
Shares issued through employee share purchase plan	$ 136,926	(56,212)			$ 80,714
Shares issued through employee share purchase plan, shares	16,506
Share-based payments		7,522,608			7,522,608
Loss for the year				(23,445,370)	(23,445,370)
Ending Balance at Sep. 30, 2020	$ 131,086,364	31,204,284	(2,076,479)	(80,970,304)	79,243,865
Ending Balance, in shares at Sep. 30, 2020	32,064,411
Share issuance costs	$ (9,229,450)				(9,229,450)
Warrants exercised	$ 3,254,460	(3,253,864)			596
Warrants exercised, in shares	6,024,807
Financing	$ 149,999,985				149,999,985
Financing , in shares	5,555,555
Options exercised	$ 2,105,467	(918,634)			$ 1,186,833
Options exercised, shares	323,610				323,610
Shares issued through employee share purchase plan	$ 198,350	(65,279)			$ 133,071
Shares issued through employee share purchase plan, shares	15,963
Share-based payments		9,476,113			9,476,113
Loss for the year				(36,805,461)	(36,805,461)
Ending Balance at Sep. 30, 2021	$ 277,415,176	$ 36,442,620	$ (2,076,479)	$ (117,775,765)	$ 194,005,552
Ending Balance, in shares at Sep. 30, 2021	43,984,346

NATURE OF OPERATIONS

NATURE OF OPERATIONS	12 Months Ended
	Sep. 30, 2021
NATURE OF OPERATIONS
NATURE OF OPERATIONS	1. NATURE OF OPERATIONS Nature of Operations ESSA Pharma Inc. (the “Company”) was incorporated under the laws of the Province of British Columbia on January 6, 2009. The Company’s head office address is Suite 720 – 999 West Broadway, Vancouver, BC, V5Z 1K5. The registered and records office address is the 26 th The Company is focused on the development of small molecule drugs for the treatment of prostate cancer. The Company has acquired a license to certain patents (the “NTD Technology”) which were the joint property of the British Columbia Cancer Agency and the University of British Columbia. As at September 30, 2021, no products are in commercial production or use. Acquisition of Realm Therapeutics plc On July 31, 2019, the Company acquired all of the issued and outstanding shares of Realm Therapeutics plc (“Realm”) pursuant to a Scheme of Arrangement as sanctioned on July 29, 2019 by the High Court of Justice in England and Wales (the “Realm Acquisition”) (Note 4).

BASIS OF PRESENTATION

BASIS OF PRESENTATION	12 Months Ended
	Sep. 30, 2021
BASIS OF PRESENTATION
BASIS OF PRESENTATION	2. BASIS OF PRESENTATION Basis of Presentation These accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). The accompanying consolidated financial statements have been prepared on a historical cost basis except for certain financial assets measured at fair value. All amounts expressed in these accompanying consolidated financial statements and the accompanying notes are expressed in United States dollars, except per share data and where otherwise indicated. References to “$” are to United States dollars and references to “C$” are to Canadian dollars. Basis of Consolidation and Functional Currency Consolidation The accounts of subsidiaries are prepared for the same reporting period as the parent company, using consistent accounting policies. Inter-company transactions, balances and unrealized gains or losses on transactions are eliminated upon consolidation. The consolidated financial statements comprise the accounts of ESSA Pharma Inc., the parent company, and its wholly owned subsidiaries. Functional Currency The functional currency of an entity is the currency of the primary economic environment in which the entity operates. The functional currency of the Company and its subsidiaries have been determined as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Country of Effective Functional ​ ​ Incorporation ​ Interest ​ Currency ​ ​ ​ ​ ​ ​ ​ ESSA Pharma Inc. Canada — US Dollar ESSA Pharmaceuticals Corp. USA 100 % US Dollar Realm Therapeutics plc (1) United Kingdom 100 % Pound Sterling Realm Therapeutics Inc. (1) USA 100 % US Dollar (1) In the process of liquidation and dissolution as at September 30, 2021. Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the derivative liabilities, the valuation of equity instruments issued for services, income taxes and the product development and relocation grant. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these consolidated financial statements. The effect of a change in an accounting estimate is recognized prospectively by including it in comprehensive income in the period of the change, if the change affects that period only, or in the period of the change and future periods, if the change affects both. Significant assumptions about the future and other sources of estimation uncertainty that management has made at the statement of financial position date, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions that have been made, relate to the following key estimates: Income tax The determination of income tax is inherently complex and requires making certain estimates and assumptions about future events. Changes in facts and circumstances as a result of income tax audits, reassessments, changes to corporate structure and associated domiciling, jurisprudence and any new legislation may result in an increase or decrease the provision for income taxes. The value of deferred tax assets is evaluated based on the probability of realization; the Company has assessed that it is improbable that such assets will be realized and has accordingly not recognized a value for deferred taxes. Derivative financial instruments Certain warrants are treated as derivative financial liabilities. The estimated fair value, based on the Black-Scholes model, is adjusted on a quarterly basis with gains or losses recognized in the statement of loss and comprehensive loss. The Black-Scholes model is based on significant assumptions such as volatility, dividend yield, expected term and liquidity discounts (Note 10). Share-based payments and compensation The Company has applied estimates with respect to the valuation of shares issued for non-cash consideration. Shares are valued at the fair value of the equity instruments granted at the date the Company receives the goods or services. The Company measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. Estimating fair value for share-based payment transactions requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the fair value of the underlying common shares, the expected life of the share option, volatility and dividend yield and making assumptions about them. The assumptions and models used for estimating fair value for share-based payment transactions are discussed in Note 11.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Sep. 30, 2021
SIGNIFICANT ACCOUNTING POLICIES
SIGNIFICANT ACCOUNTING POLICIES	3. SIGNIFICANT ACCOUNTING POLICIES Cash and cash equivalents Cash and cash equivalents consist primarily of cash in banks and high-interest savings accounts and cash collateral which are recorded at cost, which approximates fair value. Short-term investments The Company’s short-term investments consist of guaranteed investment certificates and term deposits with original maturities exceeding three months and less than one year. The investments are recorded at cost plus accrued interest, which approximates fair value. Foreign exchange Transactions in currencies other than the United States dollar are recorded at exchange rates prevailing on the dates of the transactions. At the end of each reporting period, monetary assets and liabilities of the Company that are denominated in foreign currencies are translated at the period end exchange rate while non-monetary assets and liabilities are translated at historical rates. Revenues and expenses are translated at the exchange rates approximating those in effect on the date of the transactions. Exchange gains and losses arising on translation are included in comprehensive loss. On translation of the entities whose functional currency is other than the United States dollar, revenues and expenses are translated at the exchange rates approximating those in effect on the date of the transactions. Assets and liabilities are translated at the rate of exchange at the reporting date. Translation gains and losses are recorded in other comprehensive income (loss) as the cumulative translation adjustment along with the historical effects of a change in the functional currency. Government assistance Government grants, including grants from similar bodies, consisting of investment tax credits are recorded as a reduction of the related expense or cost of the asset acquired. Government grants are recognized when there is reasonable assurance that the Company has met the requirements of the approved grant program and there is reasonable assurance that the grant will be received. Research grants that compensate the Company for expenses incurred are recognized in the statement of operations and comprehensive loss on a systematic basis in the same years in which the expenses are recognized. Grants that compensate the Company for the cost of an asset are recognized on a systematic basis over the useful life of the asset. Research and development costs Expenditures on research and development activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in profit or loss as incurred. Investment tax credits related to current expenditures are included in the determination of net income as the expenditures are incurred when there is reasonable assurance they will be realized. Fair Value of financial instruments The Company’s financial instruments consist of cash and cash equivalents, short-term investments, receivables, accounts payable and accrued liabilities, long-term debt and derivative liabilities. The Company provides disclosures that enable users to evaluate (a) the significance of financial instruments for the entity’s financial position and performance; and (b) the nature and extent of risks arising from financial instruments to which the entity is exposed during the period and at the date of the statement of financial position, and how the entity manages these risks. The Company provides information about its financial instruments measured at fair value at one of three levels according to the relative reliability of the inputs used to estimate the fair value: Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 – inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and Level 3 – inputs for the asset or liability that are not based on observable market data (unobservable inputs). The fair value of cash and cash equivalents, receivables and accounts payable and accrued liabilities approximates their carrying values due to their short term to maturity. The derivative liabilities are measured using level 3 inputs (Note 10). Share-based payments Share based payment arrangements in which the Company receives goods or services as consideration for its own equity instruments are accounted for as equity settled share-based payment transactions and measured at the fair value of at grant date. Share-based compensation The Company grants stock options to acquire common shares of the Company to directors, officers, employees and consultants. The Company has elected to early adopt ASU 2018-07 which treats the measurement of employee and nonemployee options similarly and has been applied to all periods presented. The fair value of stock options is measured on the date of grant, using the Black-Scholes option pricing model, and is recognized over the requisite service or vesting period as applicable. Consideration paid for the shares on the exercise of stock options is credited to share capital. Such value is recognized as expense over the requisite service period, net of actual forfeitures, using the accelerated attribution method. The Company recognizes forfeitures as they occur. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results, or updated estimates, differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised. Basic and diluted loss per share Basic loss per share is computed by dividing the loss available to common shareholders by the weighted average number of common shares outstanding during the year. The computation of diluted earnings per share assumes the conversion, exercise or contingent issuance of securities only when such conversion, exercise or issuance would have a dilutive effect on earnings per share. The dilutive effect of convertible securities is reflected in diluted earnings per share by application of the “if converted” method. The dilutive effect of outstanding options and warrants and their equivalents is reflected in diluted earnings per share by application of the weighted-average method. Since the Company has losses, the exercise of outstanding options and warrants has not been included in this calculation as it would be anti-dilutive. Leases At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as ROU assets and short-term and long-term lease liabilities, as applicable. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. The Company typically only includes an initial lease term in its assessment of a lease arrangement. It also considers termination options and factors those into the determination of lease payments. Options to renew a lease are not included in the assessment unless there is reasonable certainty that the Company will renew. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Income taxes Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax expense is the expected tax payable on the taxable income for the year, using tax rates enacted at period end. Deferred tax is recognized in respect of temporary differences, between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: goodwill not deductible for tax purposes and an excess of the amount for financial reporting over the tax basis of an investment in a foreign subsidiary that is essentially permanent in duration. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted at the financial position reporting date. A valuation allowance is recognized for deferred tax assets if, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets are reviewed at each reporting date and a valuation allowance is recorded to the extent that it is no longer more likely than not that the related tax benefit will be realized. Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and liabilities on a net basis. Recent accounting pronouncements adopted ASU 2018-18 – Collaborative Arrangements (Topic 808) In November 2018, the FASB issued ASU 2018-18, “Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606”. This ASU: (i) clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer, (ii) provides guidance specifying that a distinct good or service is the unit of account for evaluating whether a transaction is with a customer, and (iii) precludes a company from presenting transactions with a collaborative arrangement participant that are not in the scope of ASC 606 together with revenue from contracts with customers. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted this accounting standard as of October 1, 2020. The Company will present collaboration revenue separate from product revenues. The adoption of this new accounting standard did not have a significant impact on the Company’s consolidated financial statements. ASU 2018-15 – Intangibles – Goodwill and Other (Subtopic 350-40) In August 2018, the FASB issued ASU 2018–15, Intangibles - Goodwill and Other - Internal Use Software (Subtopic 350–40). This ASU addresses the accounting for implementation costs incurred by a customer in a cloud computing arrangement that is a service contract and also adds certain disclosure requirements related to implementation costs incurred for internal-use software and cloud computing arrangements. The amendment aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted this accounting standard as of October 1, 2020 and has applied it prospectively to all implementation costs incurred after October 1, 2020. The adoption of this new accounting standard did not have a significant impact on the Company’s consolidated financial statements. ASU 2018-13 – Fair Value Measurement (Topic 820-10) In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820-10): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which changes the fair value measurement disclosure requirements of ASC Topic 820, Fair Value Measurements and Disclosures. Under this ASU, certain disclosure requirements for fair value measurements are eliminated, amended or added. These changes aim to improve the overall usefulness of disclosures to financial statement users and reduce unnecessary costs to companies when preparing the disclosures. The Company has adopted this standard as of October 1, 2020. The adoption of the standard had no impact on the Company’s consolidated financial statements and disclosures. ASU 2019-12 – Income Taxes (Topic 740) In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes by removing certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new ASU also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates. These changes aim to improve the overall usefulness of disclosures to financial statement users and reduce unnecessary costs to companies when preparing the disclosures. The Company has adopted this standard as of October 1, 2020. The adoption of the standard had no impact on the Company’s consolidated financial statements and disclosures. ASU 2016-13 – Financial Instruments-Credit Losses (Topic 326) In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost, including trade receivables. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model that requires the use of forward-looking information to calculate credit loss estimates. This guidance is effective for annual reporting periods beginning after December 15, 2019, with early adoption permitted. The Company has adopted this standard as of October 1, 2020. The adoption of the standard had no impact on the Company’s consolidated financial statements and disclosures. ​ Recently accounting pronouncements not yet adopted ASU 2020-06 – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.” ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective January 1, 2024, for the Company. Early adoption is permitted, but no earlier than January 1, 2021, including interim periods within that year. Management is currently evaluating the effect of the adoption of ASU 2020-06 on the consolidated financial statements, but currently does not believe ASU 2020-06 will have a significant impact on the Company’s accounting. ASU 2020-10 – Codification Improvements In October 2020, the FASB issued ASU 2020-10, Codification Improvements. The guidance contains improvements to the Codification by ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements is codified in the Disclosure Section of the Codification. The guidance also contains Codifications that are varied in nature and may affect the application of the guidance in cases in which the original guidance may have been unclear. For public business entities, the amendments in the ASU are effective for fiscal years beginning after December 15, 2020. For all other entities, the amendments are effective for annual periods beginning after December 15, 2021, and interim periods within annual periods beginning after December 15, 2022. Early adoption is permitted. We do not expect the adoption of ASU 2020-10 to have a material impact on our consolidated financial statements. ASU 2021-04 – Earnings per share In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). The new ASU addresses issuer’s accounting for certain modifications or exchanges of freestanding equity-classified written call options. This amendment is effective for all entities, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company will evaluate the impact of the pronouncement closer to the effective date. ​ Recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statement presentation or disclosures.

REALM ACQUISITION

REALM ACQUISITION	12 Months Ended
	Sep. 30, 2021
REALM ACQUISITION
REALM ACQUISITION	4. REALM ACQUISITION On July 31, 2019, the Company acquired all of the issued and outstanding shares of Realm. Realm shareholders received a total of 6,718,150 common shares of the Company (“New ESSA Shares”) at a ratio of 0.05763 of a New ESSA Share per share of Realm (or 1.4409 New ESSA Shares for every one Realm ADS, representing 25 Realm shares). The fair value of the Realm net assets on July 31, 2019, substantially all of which consisted of cash, was $20,247,296. Additionally, the Company incurred issuance costs of $1,925,145. Realm is not considered to be a business under the definitions of ASU 2017-01; accordingly, the Realm Acquisition is accounted for as a financing transaction. The shares issued in connection with the acquisition of Realm were valued on the basis of the value of assets received. ​ ​ ​ ​ ​ Net assets of Realm acquired: ​ Cash ​ $ 22,244,248 Receivables and other current assets ​ 240,000 Accounts payable and accrued liabilities ​ (2,236,952) ​ ​ ​ ​ Total net assets ​ $ 20,247,296 ​

SHORT-TERM INVESTMENTS

SHORT-TERM INVESTMENTS	12 Months Ended
	Sep. 30, 2021
SHORT-TERM INVESTMENTS
SHORT-TERM INVESTMENTS	5. SHORT-TERM INVESTMENTS ​ Short-term investments consist of guaranteed investment certificates (“GICs”) held at financial institutions purchased in accordance with the Company’s treasury policy. These GICs and term deposits bear interest at 0.22%-0.40% per annum and have maturities of up to 12 months.

PREPAIDS

PREPAIDS	12 Months Ended
	Sep. 30, 2021
PREPAIDS
PREPAIDS	6. PREPAIDS ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ September 30, ​ 2021 2020 ​ ​ ​ ​ ​ ​ ​ Prepaid insurance ​ $ 1,751,052 $ 825,014 Prepaid CMC and clinical expenses and deposits ​ 240,513 ​ 650,586 Other deposits and prepaid expenses ​ 190,317 ​ 124,528 ​ ​ ​ ​ ​ ​ ​ Balance, end of year ​ $ 2,181,882 $ 1,600,128 ​

ACCOUNTS PAYABLE AND ACCRUED LI

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	12 Months Ended
	Sep. 30, 2021
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	​ 7. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ September 30, ​ 2021 2020 ​ ​ ​ ​ ​ ​ ​ Accounts payable ​ $ 1,425,871 $ 678,643 Accrued expenses ​ 2,062,441 ​ 310,604 Accrued vacation ​ 320,632 ​ 154,983 ​ ​ ​ ​ ​ ​ ​ Balance, end of year ​ $ 3,808,944 $ 1,144,230 ​

OPERATING LEASE

OPERATING LEASE	12 Months Ended
	Sep. 30, 2021
OPERATING LEASE
OPERATING LEASE	8. OPERATING LEASE The Company’s operating leases included on the balance sheet are as follows: ​ ​ ​ ​ ​ Operating lease right-of-use asset ​ Balance, September 30, 2018 and 2019 ​ $ — Addition ​ 165,486 Amortization ​ ​ (110,324) ​ ​ ​ ​ Balance, September 30, 2020 ​ $ 55,162 Addition ​ 362,588 Amortization ​ ​ (109,464) ​ ​ ​ ​ Balance, September 30, 2021 ​ $ 308,286 ​ ​ ​ ​ ​ ​ ​ ​ Operating lease liabilities ​ Balance, September 30, 2018 and 2019 ​ $ — Addition ​ 165,486 Accretion ​ ​ 12,992 Lease payments ​ ​ (119,384) ​ ​ ​ ​ Balance, September 30, 2020 ​ $ 59,094 Addition ​ ​ 362,588 Accretion ​ ​ 9,570 Lease payments ​ ​ (100,282) ​ ​ ​ ​ Balance, September 30, 2021 ​ $ 330,970 ​ The Company recognizes a right-of-use asset for the right to use the underlying asset for the lease term, and a lease liability, which represents the present value of the Company’s obligation to make payments over the lease term. The present value of the lease payments is calculated using an incremental borrowing rate as the Company’s leases do not provide an implicit interest rate. At September 30, 2021, the Company’s incremental borrowing rate was 5.0% and the remaining lease term for the South Francisco office was 32 months and Houston office was 22 months. Operating lease costs of $100,282 (2020 - $119,384) and accretion expense of $9,570 (2020 - $12,992) have been recorded in “general and administrative expenses” and “financing costs” in the statement of operations and comprehensive loss respectively.

LONG-TERM DEBT

LONG-TERM DEBT	12 Months Ended
	Sep. 30, 2021
LONG-TERM DEBT
LONG-TERM DEBT	9. LONG-TERM DEBT On November 18, 2016, Silicon Valley Bank (“SVB”) entered into a $10,000,000 capital term loan facility agreement (“SVB Term Loan”) with the Company. The Company drew down $8,000,000 from the SVB Term Loan. The option to draw an additional $2,000,000 lapsed on July 31, 2017. The SVB Term Loan bore interest at the Wall Street Journal Prime Rate (“WSJ Prime Rate”) plus 3% per annum and with a maturity date of September 1, 2020. The SVB Term Loan required a final payment of 8.6% of the amount advanced (“Final Payment”), due upon the earlier of the maturity or termination of the SVB Term Loan. The Company was required to make interest only payments until December 31, 2017. The SVB Term Loan contained a voluntary prepayment option whereby the principal amount can be prepaid in whole, or in part, for a fixed fee if a prepayment is made on or before the second anniversary of the SVB Term Loan. In the year ended September 30, 2020, the Company repaid the SVB Term Loan in full totalling $3,708,955, comprising $3,199,799 in principal, $32,235 in accrued interest, $211,079 in financing costs and the Final Payment of $688,000. In connection with the $8,000,000 draw, the Company granted an aggregate of 7,477 warrants to SVB (the “SVB Warrants”), exercisable at a price of $42.80 per share for a period of seven years until November 18, 2023, with a fair value of $167,022. The Company incurred total additional transaction costs of $220,898 related to the SVB Term Loan and First Amendment. The transaction costs and Final Payment were being amortized into profit and loss over the estimated term of the facility, being the legal term, resulting in an effective interest rate of 12.6% (2019 - 12.19%). The SVB Term Loan was fully repaid during the fiscal year ended September 30, 2020. ​ ​ ​ ​ ​ ​ SVB Term ​ ​ Loan ​ ​ ​ ​ Balance, September 30, 2018 $ 6,316,963 Principal repaid ​ (2,808,823) Interest paid ​ (401,929) Accretion ​ 602,744 ​ ​ ​ ​ Balance, September 30, 2019 $ 3,708,955 ​ ​ ​ ​ Principal repaid ​ (3,199,799) Interest paid ​ (32,235) Accretion ​ 211,079 Final payment ​ (688,000) ​ ​ ​ ​ Balance, September 30, 2020 and 2021 $ — ​

DERIVATIVE LIABILITIES

DERIVATIVE LIABILITIES	12 Months Ended
	Sep. 30, 2021
DERIVATIVE LIABILITIES
DERIVATIVE LIABILITIES	10. DERIVATIVE LIABILITIES In January 2016, the Company completed a private placement of 227,273 units of the Company at $66.00 per unit (“Unit”) for gross proceeds of $14,999,992. Each Unit consisted of one common share of the Company, one 7-year 7-Year one half 2-year 2-Year 7-Year 2-Year 7-Year 7-Year 7-Year 7-Year 7-Year Additionally, the 2016 Warrants contain provisions which may require the Company to redeem the 2016 Warrants, at the option of the holder, in the event of a major transaction, such as a change of control or sale of the Company’s assets (“Major Transaction”). The redemption value would be subject to a Black-Scholes valuation at the time of exercise. In the event the consideration for a Major Transaction payable to the common shareholders is in cash, in whole or in part, the redemption of the 2016 Warrants would be made in cash pro-rata to the composition of the consideration. The potential for a cash settlement for the 2016 Warrants outside the control of the Company, in accordance with U.S. GAAP, requires the 2016 Warrants to be treated as financial liabilities measured at fair value through profit or loss. The 2016 Warrants are not traded in an active market. Valuation The Company uses the Black-Scholes option pricing model to estimate fair value. The following weighted average assumptions were used to estimate the fair value of the derivative warrant liabilities on September 30, 2021 and 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ September 30, ​ ​ ​ 2021 ​ 2020 ​ ​ ​ ​ ​ ​ ​ ​ Risk-free interest rate 0.49 % ​ 0.22 % Expected life 1.28 years ​ 2.28 years Expected annualized volatility 86.0 % ​ 97.3 % Dividend — ​ — ​ Liquidity discount 20 % ​ 20 % ​ Sensitivity The derivative warrants are a recurring Level 3 fair value measurement. The key level 3 inputs used by management to determine the fair value are the market price, expected volatility and liquidity discount. If the market price were to increase by a factor of 10% this would increase the obligation by approximately $745,868 as at September 30, 2021. If the market price were to decrease by a factor of 10% this would decrease the obligation by approximately $429,170 as at September 30, 2021. If the volatility were to increase by 10%, this would increase the obligation by approximately $741,813 as at September 30, 2021. If the volatility were to decrease by 10%, this would decrease the obligation by approximately $423,842 as at September 30, 2021. The following table is a continuity schedule of changes to the Company’s derivative liabilities: ​ ​ ​ ​ ​ ​ Total ​ ​ ​ ​ Balance, September 30, 2018 $ 17,679 Change in fair value ​ (1,159) ​ ​ ​ ​ Balance, September 30, 2019 $ 16,520 Change in fair value ​ 110,856 ​ ​ ​ ​ Balance, September 30, 2020 $ 127,376 Change in fair value ​ (107,024) ​ ​ ​ ​ Balance, September 30, 2021 $ 20,352 ​ ​ ​ ​ Derivatives with expected life of less than one year $ — Derivatives with expected life greater than one year $ 20,352 ​

SHAREHOLDERS' EQUITY

SHAREHOLDERS' EQUITY	12 Months Ended
	Sep. 30, 2021
SHAREHOLDERS' EQUITY
SHAREHOLDERS' EQUITY	11. SHAREHOLDERS’ EQUITY Authorized Unlimited common shares, without par value. Unlimited preferred shares, without par value. February 2021 Financing On February 22, 2021, the Company completed an underwritten public offering for aggregate gross proceeds of $149,999,985 (the “ February 2021 Financing 30-day July 2020 Financing On July 31, 2020, the Company completed an underwritten public offering for aggregate gross proceeds of US$48,990,000 (the “ July 2020 Financing 30-day August 2019 Financing On August 27, 2019, the Company closed a public offering of equity securities of the Company in Canada and a concurrent private placement of equity securities in the United States (the “ August 2019 Financing Realm Acquisition On July 31, 2019, the Company issued 6,718,150 shares in relation to the Realm Acquisition (Note 4). Nomination Rights In connection with a January 2016 private placement of 227,273 Units, a Unit consisting of one common share, one 7-year one 2-year Clarus Equity incentive plans Restricted share units plan The Company has adopted a Restricted Share Unit Plan (“RSU Plan”) consistent with the policies and rules of the TSX-V and Nasdaq. Pursuant to the RSU Plan, RSUs may be granted with vesting criteria and periods are approved by the Board of Directors at its discretion. The RSUs issued under the RSU Plan may be accounted for as either equity-settled or cash-settled share-based payments. At September 30, 2021, there are no RSUs outstanding. As at September 30, 2021 the Stock Option Plan and RSU Plan have a combined maximum of 7,342,788 common shares which may be reserved for issuance. Employee Share Purchase Plan The Company has adopted an Employee Share Purchase Plan (“ESPP”) under which qualifying employees may be granted purchase rights (“Purchase Rights”) to the Company’s common shares at not less of 85% of the market price at the lesser of the date the Purchase Right is granted or exercisable. The Company currently holds offerings consisting of six-month periods commencing on January 1 and July 1 and ending on June 30 and December 31 of each calendar year. As at September 30, 2021, the ESPP has a maximum of 252,418 (2020 –268,381) common shares reserved for issuance. Eligible employees are able to contribute up to 15% of their gross base earnings for purchases under the ESPP through regular payroll deductions. Purchase of shares under the ESPP are limited for each employee at $25,000 worth of the Company’s common shares (determined using the lesser of (i) the market price of a common share on the first day of an applicable purchase period and (ii) the market price of a common share on the purchase date) for each calendar year in which a purchase right is outstanding. During the year ended September 30, 2021, the Company issued a total of 15,963 (2020 –16,506; 2019 - nil) common shares upon the exercise of Purchase Rights. The Company recognizes compensation expense for purchase rights on a straight-line basis over the service period. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the year ended September 30, ​ 2021 ​ 2020 2019 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and development expense ​ $ 32,299 $ 24,984 ​ $ — General and administrative ​ 36,132 ​ 46,033 ​ — ​ ​ $ 68,431 ​ $ 71,017 ​ $ — ​ The Company measures the purchase rights based on their estimated grant date fair value using the Black-Scholes option pricing model and the estimated number of shares that can be purchased. The following weighted average assumptions were used for the valuation of purchase rights: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2021 2020 2019 ​ ​ ​ ​ ​ ​ ​ Risk-free interest rate 0.19 % 1.44 % — Expected life of share purchase rights 6 months 6 months — Expected annualized volatility 61.54 % 90.34 % — Dividend — — — ​ Stock options The Company has adopted a Stock Option Plan consistent with the policies and rules of the TSX-V and Nasdaq. Pursuant to the Stock Option Plan, options may be granted with expiry terms of up to 10 years, and vesting criteria and periods are approved by the Board of Directors at its discretion. The options issued under the Stock Option Plan are accounted for as equity-settled share-based payments. Stock option transactions are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ Number ​ Average ​ ​ of Options ​ Exercise Price* ​ ​ ​ ​ ​ Balance, September 30, 2018 900,459 ​ $ 4.59 Options granted ​ 255,000 ​ ​ 3.77 Options expired/forfeited (32,998) ​ (4.10) ​ ​ ​ ​ ​ ​ Balance, September 30, 2019 1,122,461 ​ $ 4.59 Options granted 4,218,000 ​ 3.31 Options exercised ​ (416) ​ ​ (2.20) Options expired/forfeited (30,461) ​ (28.46) ​ ​ ​ ​ ​ ​ Balance, September 30, 2020 5,309,584 ​ $ 3.42 Options granted 1,889,646 ​ 9.87 Options exercised (323,610) ​ (3.68) Options expired/forfeited (72,390) ​ (4.46) ​ ​ ​ ​ ​ ​ Balance outstanding, September 30, 2021 6,803,230 ​ $ 5.20 Balance exercisable, September 30, 2021 2,799,226 ​ $ 3.49 * Options exercisable in Canadian dollars as at September 30, 2021 are translated at current rates to reflect the current weighted average exercise price in US dollars for all outstanding options. At September 30, 2021, options were outstanding enabling holders to acquire common shares as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average remaining ​ ​ Exercise price ​ Number of options ​ contractual life (years) ​ ​ ​ ​ ​ ​ ​ ​ $ 2.20 ​ 4,584 ​ 7.70 ​ $ 3.23 3,794,603 8.02 ​ $ 3.59 26,667 8.05 ​ $ 3.81 185,816 7.36 ​ $ 4.00 539,518 6.22 ​ $ 4.67 183,511 8.09 ​ $ 7.00 1,508,146 9.20 ​ $ 13.96 190,000 9.29 ​ $ 29.63 100,000 9.58 ​ $ 31.62 75,000 9.67 ​ C$ 4.90 163,154 5.81 ​ C$ 5.06 32,231 7.36 ​ ​ ​ 6,803,230 8.15 ​ ​ Share-based compensation During the year ended September 30, 2021, the Company granted a total of 1,889,646 (2020 – 4,218,000, 2019 - 255,000) stock options with a weighted average fair value of $8.04 per option (2020 – $2.98, 2019 - $3.00). The Company recognized share-based payments expense for options granted and vesting, net of recoveries on cancellations of unvested options, during the years ended September 30, 2021, 2020 and 2019 with allocations to its functional expense as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the year ended September 30, ​ ​ 2021 ​ 2020 ​ 2019 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and development expense ​ $ 3,611,083 $ 1,853,388 ​ $ 304,786 General and administrative ​ 5,796,599 ​ 5,598,202 ​ 841,921 ​ ​ $ 9,407,682 $ 7,451,590 ​ $ 1,146,707 ​ The following weighted average assumptions were used for the Black-Scholes option-pricing model valuation of stock options granted: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2021 2020 ​ 2019 ​ ​ ​ ​ ​ ​ ​ ​ ​ Risk-free interest rate 0.44 % 1.55 % 2.55 % Expected life of options 10.00 years 10.00 years 10.00 years Expected annualized volatility 78.16 % 77.00 % 79.33 % Dividend — — ​ — ​ ​ Warrants Warrant transactions are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ Number ​ Average ​ ​ of Warrants ​ Exercise Price ​ ​ ​ ​ ​ Balance, September 30, 2018 2,663,937 ​ $ 6.13 Warrants granted 11,919,404 ​ 0.0001 Warrants exercised (2,188,999) ​ (0.002) Warrants expired (1,250) ​ (31.17) ​ ​ ​ ​ ​ ​ Balance, September 30, 2019 12,393,092 ​ $ 1.31 Warrants exercised (3,120,115) ​ (0.08) ​ ​ ​ ​ ​ ​ Balance, September 30, 2020 9,272,977 ​ $ 1.73 Warrants exercised (6,038,227) ​ (0.06) ​ ​ ​ ​ ​ ​ Balance outstanding and exercisable, September 30, 2021 3,234,750 ​ $ 4.84 * Warrants exercisable in Canadian dollars as at September 30, 2021 are translated at current rates to reflect the current weighted average exercise price in US dollars for all outstanding warrants. At September 30, 2021, warrants were outstanding enabling holders to acquire common shares as follows: ​ ​ ​ ​ ​ ​ ​ Number ​ ​ ​ of Warrants ​ Exercise Price ​ Expiry Date ​ ​ ​ ​ ​ ​ 227,273 (1) US$ 66.00 January 14, 2023 7,477 US$ 42.80 November 18, 2023 80,000 ​ US$ 4.00 January 9, 2023 2,920,000 ​ US$ 0.0001 August 23, 2024 3,234,750 ​ (1) Detailed terms of the 2016 Warrants are included in Note 10.

SUPPLEMENTAL DISCLOSURE WITH RE

SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS	12 Months Ended
	Sep. 30, 2021
SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS
SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS	12. SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS During the year ended September 30, 2021, the Company: a) issued 81,303 common shares upon the cashless exercise of 94,723 pre-funded warrants. There were no significant non-cash financing or investing activities during the year ended September 30, 2020. During the year ended September 30, 2019, the Company: a) issued 1,652,530 common shares upon the cashless exercise of 1,653,999 pre-funded warrants; b) incurred $64,804 in transaction costs related to the Realm Transaction through accounts payable and accrued liabilities (Note 4); and c) incurred $303,951 in share issuance costs through accounts payable and accrued liabilities. ​

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Sep. 30, 2021
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS	13. RELATED PARTY TRANSACTIONS Included in accounts payable and accrued liabilities at September 30, 2021 is $82,036 (2020 - $87,846) due to related parties with respect to key management personnel compensation and expense reimbursements. Amounts due to related parties are non-interest bearing, with no fixed terms of repayment.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Sep. 30, 2021
INCOME TAXES
INCOME TAXES	14. INCOME TAXES The following is a reconciliation of income taxes calculated at the combined Canadian federal and provincial income statutory corporate tax rate of 27.0% (2020 – 27.0%, 2019 – 27.0%) to the tax expense: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the years ended September 30 2021 2020 2019 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Loss for the year before income tax ​ $ (36,839,810) $ (23,734,017) $ (12,718,912) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Tax recovery at statutory income tax rates ​ $ (9,947,000) $ (6,408,000) $ (3,434,000) Non-deductible share-based payments ​ 1,575,000 ​ 2,031,000 ​ 227,000 Taxable capital gains ​ ​ ​ — ​ 346,000 Other permanent differences including foreign exchange ​ (49,000) ​ 21,000 ​ 3,000 Share issue costs ​ (2,492,000) ​ (849,000) ​ (720,000) Change in statutory, foreign tax, foreign exchange rates and other ​ 1,260,000 ​ 1,013,000 ​ 458,000 Adjustment to prior years provision versus statutory tax returns and expiry of non-capital losses ​ (725,000) ​ (307,000) ​ (196,000) Change in valuation allowance ​ 10,344,000 ​ 4,210,000 ​ 3,354,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total income tax expense ​ $ (34,000) $ (289,000) $ 38,000 ​ Tax attributes are subject to review, and potential adjustment, by tax authorities. The Company has recorded an income tax recovery of $34,349 for the year ended September 30, 2021 (2020 – recovery of $288,647, 2019 – expense of $37,920) in relation to taxable income generated by its US subsidiary. ​ For the years ended September 30, 2021 and 2020, the Company did not record a provision for income taxes due to a full valuation allowance against our deferred tax assets. The significant components of the Company’s deferred tax assets are as follows: ​ ​ ​ ​ ​ ​ ​ ​ Deferred tax assets 2021 2020 ​ ​ ​ ​ ​ ​ ​ Operating losses carried forward ​ $ 29,749,000 $ 21,297,000 Equipment and intangible assets ​ 77,000 ​ 77,000 Investment tax credits ​ 29,000 ​ 39,000 Financing costs ​ 3,025,000 ​ 1,462,000 Federal R&D credit ​ 210,000 ​ — Other ​ 79,000 ​ — ​ ​ ​ ​ ​ ​ ​ ​ ​ 33,169,000 ​ 22,875,000 Valuation allowance ​ (33,169,000) ​ (22,875,000) ​ ​ ​ ​ ​ ​ ​ Net future tax assets ​ $ — $ — ​ ​ As at September 30, 2021, the Company has non-capital loss carry-forwards of approximately $78,416,000 (2020 - $64,494,000) available to offset future taxable income in Canada and approximately $40,843,000 (2020 - $20,249,000) available to offset future taxable income in the US. These non-capital loss carryforwards begin to expire in 2031.

SEGMENTED INFORMATION

SEGMENTED INFORMATION	12 Months Ended
	Sep. 30, 2021
SEGMENTED INFORMATION
SEGMENTED INFORMATION	15. SEGMENTED INFORMATION The Company works in one industry being the development of small molecule drugs for prostate cancer. The Company’s right of use asset is located in the USA.

FINANCIAL INSTRUMENTS AND RISK

FINANCIAL INSTRUMENTS AND RISK	12 Months Ended
	Sep. 30, 2021
FINANCIAL INSTRUMENTS AND RISK
FINANCIAL INSTRUMENTS AND RISK	16. FINANCIAL INSTRUMENTS AND RISK The Company’s financial instruments consist of cash and cash equivalents, short-term investments, receivables, accounts payable and accrued liabilities, long-term debt and derivative liabilities. The fair value of cash and cash equivalents, receivables and accounts payable and accrued liabilities approximates their carrying values due to their short term to maturity. The derivative liabilities are measured using level 3 inputs (Note 10). Fair value estimates of financial instruments are made at a specific point in time, based on relevant information about financial markets and specific financial instruments. As these estimates are subjective in nature, involving uncertainties and matters of judgement, they cannot be determined with precision. Changes in assumptions can significantly affect estimated fair values. Financial risk factors The Company’s risk exposures and the impact on the Company’s financial instruments are summarized below: Credit risk Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and cash equivalents, short-term investments and receivables. The Company’s receivables are refunds from vendors. The Company limits its exposure to credit loss by placing its cash with major financial institutions. The Company considers highly liquid investments with a maturity of up to twelve months when purchased to be short-term investments. As at September 30, 2021, cash and cash equivalents consisted of cash in Canada and the United States. and term deposits in Canada. Balances exceed amounts insured by the Canada Deposit Insurance Corporation for up to C Liquidity risk The Company’s approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As at September 30, 2021, the Company had working capital of $193,668,414. The Company does not generate revenue and will be reliant on external financing to fund operations. Debt and equity financing are dependent on market conditions and may not be available on favorable terms. Market risk Market risk is the risk of loss that may arise from changes in market factors such as interest rates, and foreign exchange rates. (a) As at September 30, 2021, the Company has cash and cash equivalents balances and GICs which are interest bearing. Interest income is not significant to the Company’s projected operational budget and related interest rate fluctuations are not significant to the Company’s risk assessment. (b) The Company’s foreign currency risk exposure relates to net monetary assets denominated in Canadian, UK pound and Euro dollars. The Company maintains its cash and cash equivalents in US dollars and converts on an as needed basis to discharge Canadian denominated expenditures. A 10% change in the foreign exchange rate between the Canadian, UK Pound, Euro and U.S. dollar in relation to Canadian, UK Pound, Euro dollars held at September 30, 2021 would result in a fluctuation of $27,261 in the net loss recognized for the period. The Company does not currently engage in hedging activities.

COMMITMENTS

COMMITMENTS	12 Months Ended
	Sep. 30, 2021
COMMITMENTS
COMMITMENTS	17. COMMITMENTS Product Development and Relocation Grant In February 2014 the Company was awarded a product development and relocation grant by CPRIT whereby the Company received $12,000,000 on eligible expenditures over a three-year period related to the development of the Company’s androgen receptor n-terminus blocker program for prostate cancer. A final payment of $229,201 was recorded as a receivable as at September 30, 2020. During the fiscal year ended September 30, 2021, the Company determined that the receivable was deemed uncollectible. The impairment of the CPRIT receivable is recorded against research and development expenses. If the Company is found to have used any grant proceeds for purposes other than intended, is in violation of the terms of the grant, or fails to maintain the required level of operations in the State of Texas for three years following the final payment of grant funds, then the Company could be required to repay any grant proceeds received. Under the terms of the grant, the Company is also required to pay a royalty to CPRIT, comprised of 4% of revenues the Company receives from sale of commercial product or commercial service, until aggregate royalty payments equal $24,000,000, and 2% of revenues thereafter. The Company has the option to terminate the grant agreement by paying a one-time, non-refundable buyout fee, based on certain factors including the grant proceeds, and the number of months between the termination date and the buyout fee payment date. License Agreement The NTD Technology is held under a license agreement signed in fiscal 2010 (the “License Agreement”). As consideration for the License Agreement, the Company issued common shares of the Company. The License Agreement contains an annual royalty as a percentage of annual net revenue and a percentage of any annual sublicensing revenue earned with respect to the NTD Technology. The License Agreement stipulates annual minimum advance royalty payments of C$85,000 . In addition, there are certain milestone payments for the first compound, to be paid in stages as to C The Company has the following obligations over the next five years: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Contractual obligations 2022 2023 2024 2025 2026 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Minimum annual royalty per License Agreement C$ 85,000 C$ 85,000 C$ 85,000 C$ 85,000 C$ 85,000 Vendor Agreement ​ C$ 25,000 ​ C$ — ​ C$ — ​ C$ — ​ C$ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Consulting Agreement ​ $ 35,000 ​ $ — ​ $ — ​ $ — ​ $ — Lease on US office spaces ​ $ 113,288 ​ $ 119,586 ​ $ 81,509 ​ $ — ​ $ — ​ Collaborative agreements ​ On February 25, 2021, the Company announced a clinical collaboration with Astellas Pharma Inc. (“Astellas”) to evaluate the combination of EPI-7386 and Astellas/Pfizer’s androgen receptor inhibitor, enzalutamide, for patients with mCRPC. Under the terms of the agreement, ESSA will sponsor and conduct a Phase 1/2 study to evaluate the safety, tolerability and preliminary efficacy of the combination of EPI-7386 and enzalutamide in mCRPC patients who have not yet been treated with second-generation antiandrogen therapies. Astellas will supply enzalutamide for the trial. ESSA will retain all rights to EPI-7386. ​ On April 28, 2021, the Company announced that it had entered into a clinical trial collaboration and supply agreement with Bayer to evaluate EPI-7386 in combination with Bayer’s androgen receptor inhibitor, darolutamide, in patients with mCRPC. Under the terms of the agreement, following review of certain clinical data, Bayer may sponsor and conduct a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of the combination of EPI-7386 and darolutamide in mCRPC patients. ESSA will supply EPI-7386 for the trial and will retain all rights to EPI-7386.

BASIS OF PRESENTATION (Policy)

BASIS OF PRESENTATION (Policy)	12 Months Ended
	Sep. 30, 2021
BASIS OF PRESENTATION
Basis of Presentation	Basis of Presentation These accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). The accompanying consolidated financial statements have been prepared on a historical cost basis except for certain financial assets measured at fair value. All amounts expressed in these accompanying consolidated financial statements and the accompanying notes are expressed in United States dollars, except per share data and where otherwise indicated. References to “$” are to United States dollars and references to “C$” are to Canadian dollars.
Basis of Consolidation and Functional Currency	Basis of Consolidation and Functional Currency Consolidation The accounts of subsidiaries are prepared for the same reporting period as the parent company, using consistent accounting policies. Inter-company transactions, balances and unrealized gains or losses on transactions are eliminated upon consolidation. The consolidated financial statements comprise the accounts of ESSA Pharma Inc., the parent company, and its wholly owned subsidiaries. Functional Currency The functional currency of an entity is the currency of the primary economic environment in which the entity operates. The functional currency of the Company and its subsidiaries have been determined as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Country of Effective Functional ​ ​ Incorporation ​ Interest ​ Currency ​ ​ ​ ​ ​ ​ ​ ESSA Pharma Inc. Canada — US Dollar ESSA Pharmaceuticals Corp. USA 100 % US Dollar Realm Therapeutics plc (1) United Kingdom 100 % Pound Sterling Realm Therapeutics Inc. (1) USA 100 % US Dollar (1) In the process of liquidation and dissolution as at September 30, 2021.
Use of Estimates	Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the derivative liabilities, the valuation of equity instruments issued for services, income taxes and the product development and relocation grant. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these consolidated financial statements. The effect of a change in an accounting estimate is recognized prospectively by including it in comprehensive income in the period of the change, if the change affects that period only, or in the period of the change and future periods, if the change affects both. Significant assumptions about the future and other sources of estimation uncertainty that management has made at the statement of financial position date, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions that have been made, relate to the following key estimates: Income tax The determination of income tax is inherently complex and requires making certain estimates and assumptions about future events. Changes in facts and circumstances as a result of income tax audits, reassessments, changes to corporate structure and associated domiciling, jurisprudence and any new legislation may result in an increase or decrease the provision for income taxes. The value of deferred tax assets is evaluated based on the probability of realization; the Company has assessed that it is improbable that such assets will be realized and has accordingly not recognized a value for deferred taxes. Derivative financial instruments Certain warrants are treated as derivative financial liabilities. The estimated fair value, based on the Black-Scholes model, is adjusted on a quarterly basis with gains or losses recognized in the statement of loss and comprehensive loss. The Black-Scholes model is based on significant assumptions such as volatility, dividend yield, expected term and liquidity discounts (Note 10). Share-based payments and compensation The Company has applied estimates with respect to the valuation of shares issued for non-cash consideration. Shares are valued at the fair value of the equity instruments granted at the date the Company receives the goods or services. The Company measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. Estimating fair value for share-based payment transactions requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the fair value of the underlying common shares, the expected life of the share option, volatility and dividend yield and making assumptions about them. The assumptions and models used for estimating fair value for share-based payment transactions are discussed in Note 11.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policy)	12 Months Ended
	Sep. 30, 2021
SIGNIFICANT ACCOUNTING POLICIES
Cash and Cash Equivalents	Cash and cash equivalents Cash and cash equivalents consist primarily of cash in banks and high-interest savings accounts and cash collateral which are recorded at cost, which approximates fair value.
Short-term Investments	Short-term investments The Company’s short-term investments consist of guaranteed investment certificates and term deposits with original maturities exceeding three months and less than one year. The investments are recorded at cost plus accrued interest, which approximates fair value.
Foreign Exchange	Foreign exchange Transactions in currencies other than the United States dollar are recorded at exchange rates prevailing on the dates of the transactions. At the end of each reporting period, monetary assets and liabilities of the Company that are denominated in foreign currencies are translated at the period end exchange rate while non-monetary assets and liabilities are translated at historical rates. Revenues and expenses are translated at the exchange rates approximating those in effect on the date of the transactions. Exchange gains and losses arising on translation are included in comprehensive loss. On translation of the entities whose functional currency is other than the United States dollar, revenues and expenses are translated at the exchange rates approximating those in effect on the date of the transactions. Assets and liabilities are translated at the rate of exchange at the reporting date. Translation gains and losses are recorded in other comprehensive income (loss) as the cumulative translation adjustment along with the historical effects of a change in the functional currency.
Government Assistance	Government assistance Government grants, including grants from similar bodies, consisting of investment tax credits are recorded as a reduction of the related expense or cost of the asset acquired. Government grants are recognized when there is reasonable assurance that the Company has met the requirements of the approved grant program and there is reasonable assurance that the grant will be received. Research grants that compensate the Company for expenses incurred are recognized in the statement of operations and comprehensive loss on a systematic basis in the same years in which the expenses are recognized. Grants that compensate the Company for the cost of an asset are recognized on a systematic basis over the useful life of the asset.
Research and Development Costs	Research and development costs Expenditures on research and development activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in profit or loss as incurred. Investment tax credits related to current expenditures are included in the determination of net income as the expenditures are incurred when there is reasonable assurance they will be realized.
Fair Value of Financial Instruments	Fair Value of financial instruments The Company’s financial instruments consist of cash and cash equivalents, short-term investments, receivables, accounts payable and accrued liabilities, long-term debt and derivative liabilities. The Company provides disclosures that enable users to evaluate (a) the significance of financial instruments for the entity’s financial position and performance; and (b) the nature and extent of risks arising from financial instruments to which the entity is exposed during the period and at the date of the statement of financial position, and how the entity manages these risks. The Company provides information about its financial instruments measured at fair value at one of three levels according to the relative reliability of the inputs used to estimate the fair value: Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 – inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and Level 3 – inputs for the asset or liability that are not based on observable market data (unobservable inputs). The fair value of cash and cash equivalents, receivables and accounts payable and accrued liabilities approximates their carrying values due to their short term to maturity. The derivative liabilities are measured using level 3 inputs (Note 10).
Share-based Payments	Share-based payments Share based payment arrangements in which the Company receives goods or services as consideration for its own equity instruments are accounted for as equity settled share-based payment transactions and measured at the fair value of at grant date. Share-based compensation The Company grants stock options to acquire common shares of the Company to directors, officers, employees and consultants. The Company has elected to early adopt ASU 2018-07 which treats the measurement of employee and nonemployee options similarly and has been applied to all periods presented. The fair value of stock options is measured on the date of grant, using the Black-Scholes option pricing model, and is recognized over the requisite service or vesting period as applicable. Consideration paid for the shares on the exercise of stock options is credited to share capital. Such value is recognized as expense over the requisite service period, net of actual forfeitures, using the accelerated attribution method. The Company recognizes forfeitures as they occur. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results, or updated estimates, differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.
Basic and Diluted Loss per Share	Basic and diluted loss per share Basic loss per share is computed by dividing the loss available to common shareholders by the weighted average number of common shares outstanding during the year. The computation of diluted earnings per share assumes the conversion, exercise or contingent issuance of securities only when such conversion, exercise or issuance would have a dilutive effect on earnings per share. The dilutive effect of convertible securities is reflected in diluted earnings per share by application of the “if converted” method. The dilutive effect of outstanding options and warrants and their equivalents is reflected in diluted earnings per share by application of the weighted-average method. Since the Company has losses, the exercise of outstanding options and warrants has not been included in this calculation as it would be anti-dilutive.
Leases	Leases At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as ROU assets and short-term and long-term lease liabilities, as applicable. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. The Company typically only includes an initial lease term in its assessment of a lease arrangement. It also considers termination options and factors those into the determination of lease payments. Options to renew a lease are not included in the assessment unless there is reasonable certainty that the Company will renew. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates. Lease expense for lease payments is recognized on a straight-line basis over the lease term.
Income Taxes	Income taxes Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax expense is the expected tax payable on the taxable income for the year, using tax rates enacted at period end. Deferred tax is recognized in respect of temporary differences, between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: goodwill not deductible for tax purposes and an excess of the amount for financial reporting over the tax basis of an investment in a foreign subsidiary that is essentially permanent in duration. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted at the financial position reporting date. A valuation allowance is recognized for deferred tax assets if, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets are reviewed at each reporting date and a valuation allowance is recorded to the extent that it is no longer more likely than not that the related tax benefit will be realized. Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and liabilities on a net basis.
Recent Accounting Pronouncements	Recent accounting pronouncements adopted ASU 2018-18 – Collaborative Arrangements (Topic 808) In November 2018, the FASB issued ASU 2018-18, “Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606”. This ASU: (i) clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer, (ii) provides guidance specifying that a distinct good or service is the unit of account for evaluating whether a transaction is with a customer, and (iii) precludes a company from presenting transactions with a collaborative arrangement participant that are not in the scope of ASC 606 together with revenue from contracts with customers. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted this accounting standard as of October 1, 2020. The Company will present collaboration revenue separate from product revenues. The adoption of this new accounting standard did not have a significant impact on the Company’s consolidated financial statements. ASU 2018-15 – Intangibles – Goodwill and Other (Subtopic 350-40) In August 2018, the FASB issued ASU 2018–15, Intangibles - Goodwill and Other - Internal Use Software (Subtopic 350–40). This ASU addresses the accounting for implementation costs incurred by a customer in a cloud computing arrangement that is a service contract and also adds certain disclosure requirements related to implementation costs incurred for internal-use software and cloud computing arrangements. The amendment aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted this accounting standard as of October 1, 2020 and has applied it prospectively to all implementation costs incurred after October 1, 2020. The adoption of this new accounting standard did not have a significant impact on the Company’s consolidated financial statements. ASU 2018-13 – Fair Value Measurement (Topic 820-10) In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820-10): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which changes the fair value measurement disclosure requirements of ASC Topic 820, Fair Value Measurements and Disclosures. Under this ASU, certain disclosure requirements for fair value measurements are eliminated, amended or added. These changes aim to improve the overall usefulness of disclosures to financial statement users and reduce unnecessary costs to companies when preparing the disclosures. The Company has adopted this standard as of October 1, 2020. The adoption of the standard had no impact on the Company’s consolidated financial statements and disclosures. ASU 2019-12 – Income Taxes (Topic 740) In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes by removing certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new ASU also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates. These changes aim to improve the overall usefulness of disclosures to financial statement users and reduce unnecessary costs to companies when preparing the disclosures. The Company has adopted this standard as of October 1, 2020. The adoption of the standard had no impact on the Company’s consolidated financial statements and disclosures. ASU 2016-13 – Financial Instruments-Credit Losses (Topic 326) In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost, including trade receivables. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model that requires the use of forward-looking information to calculate credit loss estimates. This guidance is effective for annual reporting periods beginning after December 15, 2019, with early adoption permitted. The Company has adopted this standard as of October 1, 2020. The adoption of the standard had no impact on the Company’s consolidated financial statements and disclosures. ​ Recently accounting pronouncements not yet adopted ASU 2020-06 – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.” ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective January 1, 2024, for the Company. Early adoption is permitted, but no earlier than January 1, 2021, including interim periods within that year. Management is currently evaluating the effect of the adoption of ASU 2020-06 on the consolidated financial statements, but currently does not believe ASU 2020-06 will have a significant impact on the Company’s accounting. ASU 2020-10 – Codification Improvements In October 2020, the FASB issued ASU 2020-10, Codification Improvements. The guidance contains improvements to the Codification by ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements is codified in the Disclosure Section of the Codification. The guidance also contains Codifications that are varied in nature and may affect the application of the guidance in cases in which the original guidance may have been unclear. For public business entities, the amendments in the ASU are effective for fiscal years beginning after December 15, 2020. For all other entities, the amendments are effective for annual periods beginning after December 15, 2021, and interim periods within annual periods beginning after December 15, 2022. Early adoption is permitted. We do not expect the adoption of ASU 2020-10 to have a material impact on our consolidated financial statements. ASU 2021-04 – Earnings per share In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). The new ASU addresses issuer’s accounting for certain modifications or exchanges of freestanding equity-classified written call options. This amendment is effective for all entities, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company will evaluate the impact of the pronouncement closer to the effective date. ​ Recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statement presentation or disclosures.

BASIS OF PRESENTATION (Tables)

BASIS OF PRESENTATION (Tables)	12 Months Ended
	Sep. 30, 2021
BASIS OF PRESENTATION
Schedule of Functional Currency of Company and its Subsidiaries	The functional currency of the Company and its subsidiaries have been determined as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Country of Effective Functional ​ ​ Incorporation ​ Interest ​ Currency ​ ​ ​ ​ ​ ​ ​ ESSA Pharma Inc. Canada — US Dollar ESSA Pharmaceuticals Corp. USA 100 % US Dollar Realm Therapeutics plc (1) United Kingdom 100 % Pound Sterling Realm Therapeutics Inc. (1) USA 100 % US Dollar (1) In the process of liquidation and dissolution as at September 30, 2021.

REALM ACQUISITION (Tables)

REALM ACQUISITION (Tables)	12 Months Ended
	Sep. 30, 2021
REALM ACQUISITION
Schedule of Net Assets Acquired	Realm is not considered to be a business under the definitions of ASU 2017-01; accordingly, the Realm Acquisition is accounted for as a financing transaction. The shares issued in connection with the acquisition of Realm were valued on the basis of the value of assets received. ​ ​ ​ ​ ​ Net assets of Realm acquired: ​ Cash ​ $ 22,244,248 Receivables and other current assets ​ 240,000 Accounts payable and accrued liabilities ​ (2,236,952) ​ ​ ​ ​ Total net assets ​ $ 20,247,296

PREPAIDS (Tables)

PREPAIDS (Tables)	12 Months Ended
	Sep. 30, 2021
PREPAIDS
Schedule of Prepaid Expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ September 30, ​ 2021 2020 ​ ​ ​ ​ ​ ​ ​ Prepaid insurance ​ $ 1,751,052 $ 825,014 Prepaid CMC and clinical expenses and deposits ​ 240,513 ​ 650,586 Other deposits and prepaid expenses ​ 190,317 ​ 124,528 ​ ​ ​ ​ ​ ​ ​ Balance, end of year ​ $ 2,181,882 $ 1,600,128

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)	12 Months Ended
	Sep. 30, 2021
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
Schedule of Accounts Payable and Accrued Liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ September 30, ​ 2021 2020 ​ ​ ​ ​ ​ ​ ​ Accounts payable ​ $ 1,425,871 $ 678,643 Accrued expenses ​ 2,062,441 ​ 310,604 Accrued vacation ​ 320,632 ​ 154,983 ​ ​ ​ ​ ​ ​ ​ Balance, end of year ​ $ 3,808,944 $ 1,144,230

OPERATING LEASE (Tables)

OPERATING LEASE (Tables)	12 Months Ended
	Sep. 30, 2021
OPERATING LEASE
Schedule of Operating Leases	The Company’s operating leases included on the balance sheet are as follows: ​ ​ ​ ​ ​ Operating lease right-of-use asset ​ Balance, September 30, 2018 and 2019 ​ $ — Addition ​ 165,486 Amortization ​ ​ (110,324) ​ ​ ​ ​ Balance, September 30, 2020 ​ $ 55,162 Addition ​ 362,588 Amortization ​ ​ (109,464) ​ ​ ​ ​ Balance, September 30, 2021 ​ $ 308,286 ​ ​ ​ ​ ​ ​ ​ ​ Operating lease liabilities ​ Balance, September 30, 2018 and 2019 ​ $ — Addition ​ 165,486 Accretion ​ ​ 12,992 Lease payments ​ ​ (119,384) ​ ​ ​ ​ Balance, September 30, 2020 ​ $ 59,094 Addition ​ ​ 362,588 Accretion ​ ​ 9,570 Lease payments ​ ​ (100,282) ​ ​ ​ ​ Balance, September 30, 2021 ​ $ 330,970

LONG-TERM DEBT (Tables)

LONG-TERM DEBT (Tables)	12 Months Ended
	Sep. 30, 2021
LONG-TERM DEBT
Schedule of Term Loan Repayment	The SVB Term Loan was fully repaid during the fiscal year ended September 30, 2020. ​ ​ ​ ​ ​ ​ SVB Term ​ ​ Loan ​ ​ ​ ​ Balance, September 30, 2018 $ 6,316,963 Principal repaid ​ (2,808,823) Interest paid ​ (401,929) Accretion ​ 602,744 ​ ​ ​ ​ Balance, September 30, 2019 $ 3,708,955 ​ ​ ​ ​ Principal repaid ​ (3,199,799) Interest paid ​ (32,235) Accretion ​ 211,079 Final payment ​ (688,000) ​ ​ ​ ​ Balance, September 30, 2020 and 2021 $ —

DERIVATIVE LIABILITIES (Tables)

DERIVATIVE LIABILITIES (Tables)	12 Months Ended
	Sep. 30, 2021
DERIVATIVE LIABILITIES
Fair Value Measurement Inputs and Valuation Techniques	The Company uses the Black-Scholes option pricing model to estimate fair value. The following weighted average assumptions were used to estimate the fair value of the derivative warrant liabilities on September 30, 2021 and 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ September 30, ​ ​ ​ 2021 ​ 2020 ​ ​ ​ ​ ​ ​ ​ ​ Risk-free interest rate 0.49 % ​ 0.22 % Expected life 1.28 years ​ 2.28 years Expected annualized volatility 86.0 % ​ 97.3 % Dividend — ​ — ​ Liquidity discount 20 % ​ 20 %
Schedule of Changes to Derivative Liabilities	The following table is a continuity schedule of changes to the Company’s derivative liabilities: ​ ​ ​ ​ ​ ​ Total ​ ​ ​ ​ Balance, September 30, 2018 $ 17,679 Change in fair value ​ (1,159) ​ ​ ​ ​ Balance, September 30, 2019 $ 16,520 Change in fair value ​ 110,856 ​ ​ ​ ​ Balance, September 30, 2020 $ 127,376 Change in fair value ​ (107,024) ​ ​ ​ ​ Balance, September 30, 2021 $ 20,352 ​ ​ ​ ​ Derivatives with expected life of less than one year $ — Derivatives with expected life greater than one year $ 20,352

SHAREHOLDERS' EQUITY (Tables)

SHAREHOLDERS' EQUITY (Tables)	12 Months Ended
	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Stock Option Activity	Stock option transactions are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ Number ​ Average ​ ​ of Options ​ Exercise Price* ​ ​ ​ ​ ​ Balance, September 30, 2018 900,459 ​ $ 4.59 Options granted ​ 255,000 ​ ​ 3.77 Options expired/forfeited (32,998) ​ (4.10) ​ ​ ​ ​ ​ ​ Balance, September 30, 2019 1,122,461 ​ $ 4.59 Options granted 4,218,000 ​ 3.31 Options exercised ​ (416) ​ ​ (2.20) Options expired/forfeited (30,461) ​ (28.46) ​ ​ ​ ​ ​ ​ Balance, September 30, 2020 5,309,584 ​ $ 3.42 Options granted 1,889,646 ​ 9.87 Options exercised (323,610) ​ (3.68) Options expired/forfeited (72,390) ​ (4.46) ​ ​ ​ ​ ​ ​ Balance outstanding, September 30, 2021 6,803,230 ​ $ 5.20 Balance exercisable, September 30, 2021 2,799,226 ​ $ 3.49 * Options exercisable in Canadian dollars as at September 30, 2021 are translated at current rates to reflect the current weighted average exercise price in US dollars for all outstanding options.
Summary of Stock Option Outstanding	At September 30, 2021, options were outstanding enabling holders to acquire common shares as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average remaining ​ ​ Exercise price ​ Number of options ​ contractual life (years) ​ ​ ​ ​ ​ ​ ​ ​ $ 2.20 ​ 4,584 ​ 7.70 ​ $ 3.23 3,794,603 8.02 ​ $ 3.59 26,667 8.05 ​ $ 3.81 185,816 7.36 ​ $ 4.00 539,518 6.22 ​ $ 4.67 183,511 8.09 ​ $ 7.00 1,508,146 9.20 ​ $ 13.96 190,000 9.29 ​ $ 29.63 100,000 9.58 ​ $ 31.62 75,000 9.67 ​ C$ 4.90 163,154 5.81 ​ C$ 5.06 32,231 7.36 ​ ​ ​ 6,803,230 8.15 ​ ​
Summary of Warrants Activity	Warrant transactions are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ Number ​ Average ​ ​ of Warrants ​ Exercise Price ​ ​ ​ ​ ​ Balance, September 30, 2018 2,663,937 ​ $ 6.13 Warrants granted 11,919,404 ​ 0.0001 Warrants exercised (2,188,999) ​ (0.002) Warrants expired (1,250) ​ (31.17) ​ ​ ​ ​ ​ ​ Balance, September 30, 2019 12,393,092 ​ $ 1.31 Warrants exercised (3,120,115) ​ (0.08) ​ ​ ​ ​ ​ ​ Balance, September 30, 2020 9,272,977 ​ $ 1.73 Warrants exercised (6,038,227) ​ (0.06) ​ ​ ​ ​ ​ ​ Balance outstanding and exercisable, September 30, 2021 3,234,750 ​ $ 4.84 * Warrants exercisable in Canadian dollars as at September 30, 2021 are translated at current rates to reflect the current weighted average exercise price in US dollars for all outstanding warrants.
Summary of Warrants Outstanding	At September 30, 2021, warrants were outstanding enabling holders to acquire common shares as follows: ​ ​ ​ ​ ​ ​ ​ Number ​ ​ ​ of Warrants ​ Exercise Price ​ Expiry Date ​ ​ ​ ​ ​ ​ 227,273 (1) US$ 66.00 January 14, 2023 7,477 US$ 42.80 November 18, 2023 80,000 ​ US$ 4.00 January 9, 2023 2,920,000 ​ US$ 0.0001 August 23, 2024 3,234,750 ​ (1) Detailed terms of the 2016 Warrants are included in Note 10.
Employee Share Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share Based Compensation Expense	During the year ended September 30, 2021, the Company issued a total of 15,963 (2020 –16,506; 2019 - nil) common shares upon the exercise of Purchase Rights. The Company recognizes compensation expense for purchase rights on a straight-line basis over the service period. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the year ended September 30, ​ 2021 ​ 2020 2019 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and development expense ​ $ 32,299 $ 24,984 ​ $ — General and administrative ​ 36,132 ​ 46,033 ​ — ​ ​ $ 68,431 ​ $ 71,017 ​ $ —
Weighted Average Assumptions for the Valuation of Stock Options	The Company measures the purchase rights based on their estimated grant date fair value using the Black-Scholes option pricing model and the estimated number of shares that can be purchased. The following weighted average assumptions were used for the valuation of purchase rights: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2021 2020 2019 ​ ​ ​ ​ ​ ​ ​ Risk-free interest rate 0.19 % 1.44 % — Expected life of share purchase rights 6 months 6 months — Expected annualized volatility 61.54 % 90.34 % — Dividend — — —
Stock Options Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share Based Compensation Expense	The Company recognized share-based payments expense for options granted and vesting, net of recoveries on cancellations of unvested options, during the years ended September 30, 2021, 2020 and 2019 with allocations to its functional expense as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the year ended September 30, ​ ​ 2021 ​ 2020 ​ 2019 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and development expense ​ $ 3,611,083 $ 1,853,388 ​ $ 304,786 General and administrative ​ 5,796,599 ​ 5,598,202 ​ 841,921 ​ ​ $ 9,407,682 $ 7,451,590 ​ $ 1,146,707
Weighted Average Assumptions for the Valuation of Stock Options	The following weighted average assumptions were used for the Black-Scholes option-pricing model valuation of stock options granted: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2021 2020 ​ 2019 ​ ​ ​ ​ ​ ​ ​ ​ ​ Risk-free interest rate 0.44 % 1.55 % 2.55 % Expected life of options 10.00 years 10.00 years 10.00 years Expected annualized volatility 78.16 % 77.00 % 79.33 % Dividend — — ​ — ​ ​

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Sep. 30, 2021
INCOME TAXES
Reconciliation of Income Taxes at Statutory Rates	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the years ended September 30 2021 2020 2019 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Loss for the year before income tax ​ $ (36,839,810) $ (23,734,017) $ (12,718,912) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Tax recovery at statutory income tax rates ​ $ (9,947,000) $ (6,408,000) $ (3,434,000) Non-deductible share-based payments ​ 1,575,000 ​ 2,031,000 ​ 227,000 Taxable capital gains ​ ​ ​ — ​ 346,000 Other permanent differences including foreign exchange ​ (49,000) ​ 21,000 ​ 3,000 Share issue costs ​ (2,492,000) ​ (849,000) ​ (720,000) Change in statutory, foreign tax, foreign exchange rates and other ​ 1,260,000 ​ 1,013,000 ​ 458,000 Adjustment to prior years provision versus statutory tax returns and expiry of non-capital losses ​ (725,000) ​ (307,000) ​ (196,000) Change in valuation allowance ​ 10,344,000 ​ 4,210,000 ​ 3,354,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total income tax expense ​ $ (34,000) $ (289,000) $ 38,000
Significant Components of Future Tax Assets	​ ​ ​ ​ ​ ​ ​ ​ Deferred tax assets 2021 2020 ​ ​ ​ ​ ​ ​ ​ Operating losses carried forward ​ $ 29,749,000 $ 21,297,000 Equipment and intangible assets ​ 77,000 ​ 77,000 Investment tax credits ​ 29,000 ​ 39,000 Financing costs ​ 3,025,000 ​ 1,462,000 Federal R&D credit ​ 210,000 ​ — Other ​ 79,000 ​ — ​ ​ ​ ​ ​ ​ ​ ​ ​ 33,169,000 ​ 22,875,000 Valuation allowance ​ (33,169,000) ​ (22,875,000) ​ ​ ​ ​ ​ ​ ​ Net future tax assets ​ $ — $ —

COMMITMENTS (Tables)

COMMITMENTS (Tables)	12 Months Ended
	Sep. 30, 2021
COMMITMENTS
Schedule of Contractual Obligations	The Company has the following obligations over the next five years: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Contractual obligations 2022 2023 2024 2025 2026 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Minimum annual royalty per License Agreement C$ 85,000 C$ 85,000 C$ 85,000 C$ 85,000 C$ 85,000 Vendor Agreement ​ C$ 25,000 ​ C$ — ​ C$ — ​ C$ — ​ C$ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Consulting Agreement ​ $ 35,000 ​ $ — ​ $ — ​ $ — ​ $ — Lease on US office spaces ​ $ 113,288 ​ $ 119,586 ​ $ 81,509 ​ $ — ​ $ —

NATURE OF OPERATIONS (Narrative

NATURE OF OPERATIONS (Narrative) (Details) - Realm Therapeutics Plc [Member]	Jul. 31, 2019
Acquisition date	Jul. 31, 2019
Name of acquired entity	Realm Therapeutics plc (“Realm”)

BASIS OF PRESENTATION (Schedule

BASIS OF PRESENTATION (Schedule of Functional Currency of Company and its Subsidiaries) (Details)	12 Months Ended
	Sep. 30, 2021
ESSA Pharmaceuticals Corp [Member]
Basis of Presentation [Line Items]
Effective interest	100.00%
Realm Therapeutics Plc [Member]
Basis of Presentation [Line Items]
Effective interest	100.00%
Realm Therapeutics Inc [Member]
Basis of Presentation [Line Items]
Effective interest	100.00%

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($)	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Significant Accounting Policies [Line Items]
Operating lease right-of-use assets	$ 308,286	$ 0	$ 0
Operating lease liabilities	330,970	59,094	$ 0
Accumulated deficit	$ (117,775,765)	(80,970,304)
ASU 2016-02 [Member]
Significant Accounting Policies [Line Items]
Operating lease right-of-use assets		165,486
Operating lease liabilities		$ 165,486

REALM ACQUISITION (Narrative) (

REALM ACQUISITION (Narrative) (Details) - Realm Therapeutics Plc [Member]	Jul. 31, 2019USD ($)shares
Realm acquisition
Acquisition date	Jul. 31, 2019
Name of acquired entity	Realm Therapeutics plc (“Realm”)
New shares issued on acquisition | shares	6,718,150
Conversion ratio per share	0.05763
Conversion ratio per American Depository Share (ADS)	1.4409
Number of shares represented by each American Depository Share (ADS) | shares	25
Fair value of net assets acquired | $	$ 20,247,296
Issuance costs incurred | $	$ 1,925,145

REALM ACQUISITION (Schedule of

REALM ACQUISITION (Schedule of Net Assets Acquired) (Details) - Realm Therapeutics Plc [Member]	Jul. 31, 2019USD ($)
Net assets of Realm acquired:
Cash	$ 22,244,248
Receivables and other current assets	240,000
Accounts payable and accrued liabilities	(2,236,952)
Total net assets	$ 20,247,296

SHORT-TERM INVESTMENTS (Narrati

SHORT-TERM INVESTMENTS (Narrative) (Details)	Sep. 30, 2021
Maximum [Member]
Guaranteed investment certificates, interest rate	0.40%
Minimum [Member]
Guaranteed investment certificates, interest rate	0.22%

PREPAIDS (Schedule of Prepaid E

PREPAIDS (Schedule of Prepaid Expenses) (Details) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
PREPAIDS
Prepaid insurance	$ 1,751,052	$ 825,014
Prepaid CMC and clinical expenses and deposits	240,513	650,586
Other deposits and prepaid expenses	190,317	124,528
Balance, end of year	$ 2,181,882	$ 1,600,128

ACCOUNTS PAYABLE AND ACCRUED _3

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Schedule of Accounts Payable and Accrued Liabilities) (Details) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
Accounts payable	$ 1,425,871	$ 678,643
Accrued expenses	2,062,441	310,604
Accrued vacation	320,632	154,983
Balance, end of year	$ 3,808,944	$ 1,144,230

OPERATING LEASE (Narrative) (De

OPERATING LEASE (Narrative) (Details) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Incremental borrowing rate	5.00%
Operating lease costs		$ 119,384
Accretion expense	$ 9,570	$ 12,992
South San Francisco Office [Member]
Remaining lease term	32 months
Houston Office [Member]
Remaining lease term	22 months
General and Administrative [Member]
Operating lease costs	$ 100,282
Financing costs [Member]
Accretion expense	$ 9,570

OPERATING LEASE (Schedule of Op

OPERATING LEASE (Schedule of Operating Leases) (Details) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Operating lease right-of-use asset
Operating lease right-of-use assets	$ 308,286	$ 0	$ 0
Operating lease right-of-use assets, current	0	55,162
Addition	362,588
Amortization	(109,464)	(110,324)	0
Operating lease liabilities
Operating lease liabilities	330,970	59,094	$ 0
Addition	362,588
Accretion	9,570	12,992
Lease payments	$ (100,282)	(119,384)
ASU 2016-02 [Member]
Operating lease right-of-use asset
Operating lease right-of-use assets		165,486
Operating lease liabilities
Operating lease liabilities		$ 165,486

LONG-TERM DEBT (Narrative) (Det

LONG-TERM DEBT (Narrative) (Details) - USD ($)	Nov. 18, 2016	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2018	Jul. 31, 2017
LONG-TERM DEBT
Exercise price (in dollars per share)		$ 4.84	$ 1.73	$ 1.31	$ 6.13
Financing costs		$ 0	$ 32,235	$ 401,929
Warrants granted (in shares)				11,919,404
SVB Term Loan [Member]
LONG-TERM DEBT
Term loan	$ 10,000,000
Amount drawn from term loan facility	$ 8,000,000
Borrowing capacity lapsed						$ 2,000,000
Exercise price (in dollars per share)	$ 42.80
Debt maturity date	Sep. 1, 2020
Percentage of final payment	8.60%
Total Loan payment			3,708,955
Principal amount paid		3,199,799	3,199,799	$ 2,808,823
Interest paid		32,235	32,235	$ 401,929
Financing costs		211,079
Final payment		$ 688,000	$ 688,000
Warrants granted (in shares)	7,477
Term of warrant	7 years
Fair value of warrant issued	$ 167,022
Additional transaction cost	$ 220,898
Effective interest rate		12.60%	12.19%
SVB Term Loan [Member] | WSJ Prime Rate [Member]
LONG-TERM DEBT
Variable rate of interest	3.00%

LONG-TERM DEBT (Schedule of Ter

LONG-TERM DEBT (Schedule of Term Loan Repayment) (Details) - SVB Term Loan [Member] - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
LONG-TERM DEBT
Long term debt, Beginning balance		$ 3,708,955	$ 6,316,963
Principal repaid	$ (3,199,799)	(3,199,799)	(2,808,823)
Interest paid	(32,235)	(32,235)	(401,929)
Accretion		211,079	602,744
Final payment	(688,000)	$ (688,000)
Long term debt, Ending balance	$ 0		$ 3,708,955

DERIVATIVE LIABILITIES (Narrati

DERIVATIVE LIABILITIES (Narrative) (Details)	1 Months Ended
	Jan. 31, 2016USD ($)$ / sharesshares	Sep. 30, 2021USD ($)$ / shares	Sep. 30, 2020$ / shares	Sep. 30, 2019$ / shares	Sep. 30, 2018$ / shares
DERIVATIVE LIABILITIES
Exercise price (in dollars per share) | $ / shares		$ 4.84	$ 1.73	$ 1.31	$ 6.13
Level 3 [Member] | Increase in market Price of warrants by 10% [Member]
DERIVATIVE LIABILITIES
Increase (decrease) in derivative liability due to change in market price		$ 745,868
Level 3 [Member] | Decrease in market Price of warrants by 10% [Member]
DERIVATIVE LIABILITIES
Increase (decrease) in derivative liability due to change in market price		429,170
Level 3 [Member] | Increase in Volatility of warrants by 10% [Member]
DERIVATIVE LIABILITIES
Increase (decrease) in derivative liability due to change in volatility		741,813
Level 3 [Member] | Decrease in Volatility of warrants by 10% [Member]
DERIVATIVE LIABILITIES
Increase (decrease) in derivative liability due to change in volatility		$ 423,842
Private Placement [Member]
DERIVATIVE LIABILITIES
Shares issued | shares	227,273
Unit price (in dollars per share) | $ / shares	$ 66
Fair value of units issued	$ 14,999,992
Exercise price (in dollars per share) | $ / shares	$ 66
Units issued in private placement, conversion ratio	1
Private Placement [Member] | 2 Year Warrants [Member]
DERIVATIVE LIABILITIES
Units issued in private placement, conversion ratio	0.5
Term of warrant	2 years
Private Placement [Member] | 7 Year Warrants [Member]
DERIVATIVE LIABILITIES
Units issued in private placement, conversion ratio	1
Term of warrant	7 years

DERIVATIVE LIABILITIES (Fair Va

DERIVATIVE LIABILITIES (Fair Value Measurement Inputs and Valuation Techniques) (Details) - Weighted Average [Member]	Sep. 30, 2021Y	Sep. 30, 2020Y
Risk-free Interest Rate [Member]
DERIVATIVE LIABILITIES
Assumptions to fair value of the derivative warrant liabilities	0.0049	0.0022
Expected Life [Member]
DERIVATIVE LIABILITIES
Assumptions to fair value of the derivative warrant liabilities	1.28	2.28
Expected Annualized Volatility [Member]
DERIVATIVE LIABILITIES
Assumptions to fair value of the derivative warrant liabilities	0.860	0.973
Dividend [Member]
DERIVATIVE LIABILITIES
Assumptions to fair value of the derivative warrant liabilities	0	0
Liquidity Discount [Member]
DERIVATIVE LIABILITIES
Assumptions to fair value of the derivative warrant liabilities	0.20	0.20

DERIVATIVE LIABILITIES (Schedul

DERIVATIVE LIABILITIES (Schedule of Changes of Derivative Liabilities) (Details) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
DERIVATIVE LIABILITIES
Beginning balance	$ 127,376	$ 16,520	$ 17,679
Change in fair value	(107,024)	110,856	(1,159)
Ending balance	20,352	127,376	16,520
Derivatives with expected life of less than one year	0
Derivatives with expected life greater than one year	$ 20,352	$ 127,376	$ 16,520

SHAREHOLDERS' EQUITY (Narrative

SHAREHOLDERS' EQUITY (Narrative) (Details)	Feb. 22, 2021USD ($)$ / sharesshares	Jul. 31, 2020USD ($)$ / sharesshares	Aug. 27, 2019USD ($)$ / sharesshares	Jul. 31, 2019shares	Jan. 31, 2016$ / sharesshares	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2020USD ($)$ / sharesshares	Sep. 30, 2019USD ($)$ / sharesshares
SHAREHOLDERS' EQUITY
Aggregate gross proceeds | $						$ 149,999,985	$ 48,990,000	$ 36,000,000
Share issuance transaction costs | $						$ 9,229,450	$ 3,447,954	$ 2,362,329
Options granted						1,889,646	4,218,000	255,000
Weighted average fair value of options granted | $ / shares						$ 8.04	$ 2.98	$ 3
Employee Share Purchase Plan [Member]
SHAREHOLDERS' EQUITY
Shares issued						15,963	16,506	0
Offering term						6 months
Maximum eligibility to common shares amount | $						$ 25,000
Stock Options [Member]
SHAREHOLDERS' EQUITY
Option expiration period						10 years
RSU's [Member]
SHAREHOLDERS' EQUITY
RSUs outstanding						0
Minimum [Member] | Employee Share Purchase Plan [Member]
SHAREHOLDERS' EQUITY
Price percentage of common share granted						85.00%
Maximum [Member] | Employee Share Purchase Plan [Member]
SHAREHOLDERS' EQUITY
Common shares reserved for issuance						252,418	268,381
Employee contribution percentage						15.00%
Maximum [Member] | Stock Options and RSU Plan [Member]
SHAREHOLDERS' EQUITY
Common shares reserved for issuance						7,342,788
Realm Therapeutics Plc [Member]
SHAREHOLDERS' EQUITY
New shares issued on acquisition				6,718,150
February 2021 Financing [Member]
SHAREHOLDERS' EQUITY
Aggregate gross proceeds | $	$ 149,999,985
Shares issued	5,555,555
Offering price per share | $ / shares	$ 27
Underwriter option to purchase additional securities	724,637
Term of underwriters option	30 days
Cash commissions paid | $	$ 8,999,999
Share issuance transaction costs | $	$ 229,451
July 2020 Financing [Member]
SHAREHOLDERS' EQUITY
Aggregate gross proceeds | $		$ 48,990,000
Shares issued		7,100,000
Offering price per share | $ / shares		$ 6
Term of underwriters option		30 days
Cash commissions paid | $		$ 2,939,400
Share issuance transaction costs | $		$ 212,256
August 2019 Financing [Member]
SHAREHOLDERS' EQUITY
Aggregate gross proceeds | $			$ 36,000,000
Shares issued			6,080,596
Offering price per share | $ / shares			$ 2
Number of pre funded warrants issued			11,919,404
Conversion of each prefunded warrant into common share			1
Term of warrant			5 years
Cash commissions paid | $			$ 1,978,770
Share issuance transaction costs | $			$ 698,162
Over Allotment Option [Member]
SHAREHOLDERS' EQUITY
Shares issued		1,065,000
Private Placement [Member]
SHAREHOLDERS' EQUITY
Shares issued					227,273
Offering price per share | $ / shares					$ 66
Units issued in private placement, conversion ratio					1
Private Placement [Member] | 2 Year Warrants [Member]
SHAREHOLDERS' EQUITY
Term of warrant					2 years
Units issued in private placement, conversion ratio					0.5
Private Placement [Member] | 7 Year Warrants [Member]
SHAREHOLDERS' EQUITY
Term of warrant					7 years
Units issued in private placement, conversion ratio					1
Private Placement [Member] | Clarus Lifesciences III, L.P [Member]
SHAREHOLDERS' EQUITY
Shares issued					106,061
Minimum number of shares required to be held for nomination rights					53,030

SHAREHOLDERS' EQUITY (Schedule

SHAREHOLDERS' EQUITY (Schedule of Share Based Compensation Expenses) (Details) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Employee Share Purchase Plan [Member]
SHAREHOLDERS' EQUITY
Compensation Expense	$ 68,431	$ 71,017	$ 0
Employee Share Purchase Plan [Member] | Research and Development [Member]
SHAREHOLDERS' EQUITY
Compensation Expense	32,299	24,984	0
Employee Share Purchase Plan [Member] | General and Administrative [Member]
SHAREHOLDERS' EQUITY
Compensation Expense	36,132	46,033	0
Stock Options Plan [Member]
SHAREHOLDERS' EQUITY
Compensation Expense	9,407,682	7,451,590	1,146,707
Stock Options Plan [Member] | Research and Development [Member]
SHAREHOLDERS' EQUITY
Compensation Expense	3,611,083	1,853,388	304,786
Stock Options Plan [Member] | General and Administrative [Member]
SHAREHOLDERS' EQUITY
Compensation Expense	$ 5,796,599	$ 5,598,202	$ 841,921

SHAREHOLDERS' EQUITY (Weighted

SHAREHOLDERS' EQUITY (Weighted Average Assumptions for the Valuation of Purchase Rights) (Details)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Employee Share Purchase Plan [Member]
Weighted average assumptions
Risk-free interest rate	0.19%	1.44%	0.00%
Expected life of share purchase options	6 months	6 months
Expected annualized volatility	61.54%	90.34%	0.00%
Dividend	0.00%	0.00%	0.00%
Stock Options Plan [Member]
Weighted average assumptions
Risk-free interest rate	0.44%	1.55%	2.55%
Expected life of share purchase options	10 years	10 years	10 years
Expected annualized volatility	78.16%	77.00%	79.33%
Dividend	0.00%	0.00%	0.00%

SHAREHOLDERS' EQUITY (Summary o

SHAREHOLDERS' EQUITY (Summary of Stock Option Activity) (Details) - $ / shares	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Number of Options
Beginning balance (in shares)	5,309,584	1,122,461	900,459
Options granted (in shares)	1,889,646	4,218,000	255,000
Options exercised (in shares)	(323,610)	(416)
Options expired/forfeited (in shares)	(72,390)	(30,461)	(32,998)
Ending balance (in shares)	6,803,230	5,309,584	1,122,461
Balance exercisable (in shares)	2,799,226
Weighted Average Exercise Price
Beginning balance (in dollars per share)	$ 3.42	$ 4.59	$ 4.59
Options granted (in dollars per share)	9.87	3.31	3.77
Options exercised (in dollars per share)	(3.68)	(2.20)
Options expired/forfeited (in dollars per share)	(4.46)	(28.46)	(4.10)
Ending balance (in dollars per share)	5.20	$ 3.42	$ 4.59
Options exercisable (in dollars per share)	$ 3.49

SHAREHOLDERS' EQUITY (Summary_2

SHAREHOLDERS' EQUITY (Summary of Stock Option Outstanding) (Details)	12 Months Ended
	Sep. 30, 2021$ / sharesshares	Sep. 30, 2021$ / sharesshares	Sep. 30, 2020$ / sharesshares	Sep. 30, 2019$ / sharesshares	Sep. 30, 2018$ / sharesshares
SHAREHOLDERS' EQUITY
Stock options, Exercise price | $ / shares	$ 5.20		$ 3.42	$ 4.59	$ 4.59
Number of options | shares	6,803,230	6,803,230	5,309,584	1,122,461	900,459
Weighted average remaining contractual life (years)	8 years 1 month 24 days
Exercise Price $2.20 [Member]
SHAREHOLDERS' EQUITY
Stock options, Exercise price | $ / shares	$ 2.20
Number of options | shares	4,584	4,584
Weighted average remaining contractual life (years)	7 years 8 months 12 days
Exercise Price $3.23 [Member]
SHAREHOLDERS' EQUITY
Stock options, Exercise price | $ / shares	$ 3.23
Number of options | shares	3,794,603	3,794,603
Weighted average remaining contractual life (years)	8 years 7 days
Exercise Price $3.59 [Member]
SHAREHOLDERS' EQUITY
Stock options, Exercise price | $ / shares	$ 3.59
Number of options | shares	26,667	26,667
Weighted average remaining contractual life (years)	8 years 18 days
Exercise Price $3.81 [Member]
SHAREHOLDERS' EQUITY
Stock options, Exercise price | $ / shares	$ 3.81
Number of options | shares	185,816	185,816
Weighted average remaining contractual life (years)	7 years 4 months 9 days
Exercise Price $4.00 [Member]
SHAREHOLDERS' EQUITY
Stock options, Exercise price | $ / shares	$ 4
Number of options | shares	539,518	539,518
Weighted average remaining contractual life (years)	6 years 2 months 19 days
Exercise Price $4.67 [Member]
SHAREHOLDERS' EQUITY
Stock options, Exercise price | $ / shares	$ 4.67
Number of options | shares	183,511	183,511
Weighted average remaining contractual life (years)	8 years 1 month 2 days
Exercise Price $7.00 [Member]
SHAREHOLDERS' EQUITY
Stock options, Exercise price | $ / shares	$ 7
Number of options | shares	1,508,146	1,508,146
Weighted average remaining contractual life (years)	9 years 2 months 12 days
Exercise Price $13.96 [Member]
SHAREHOLDERS' EQUITY
Stock options, Exercise price | $ / shares	$ 13.96
Number of options | shares	190,000	190,000
Weighted average remaining contractual life (years)	9 years 3 months 14 days
Exercise Price $29.63 [Member]
SHAREHOLDERS' EQUITY
Stock options, Exercise price | $ / shares	$ 29.63
Number of options | shares	100,000	100,000
Weighted average remaining contractual life (years)	9 years 6 months 29 days
Exercise Price $31.62 [Member]
SHAREHOLDERS' EQUITY
Stock options, Exercise price | $ / shares	$ 31.62
Number of options | shares	75,000	75,000
Weighted average remaining contractual life (years)	9 years 8 months 1 day
Exercise Price C$4.90 [Member]
SHAREHOLDERS' EQUITY
Stock options, Exercise price | $ / shares		$ 4.90
Number of options | shares	163,154	163,154
Weighted average remaining contractual life (years)	5 years 9 months 21 days
Exercise Price C$5.06 [Member]
SHAREHOLDERS' EQUITY
Stock options, Exercise price | $ / shares		$ 5.06
Number of options | shares	32,231	32,231
Weighted average remaining contractual life (years)	7 years 4 months 9 days

SHAREHOLDERS' EQUITY (Summary_3

SHAREHOLDERS' EQUITY (Summary of Warrants Activity) (Details) - $ / shares	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Number of Warrants
Number of Warrants, Beginning balance (in shares)	9,272,977	12,393,092	2,663,937
Warrants granted (in shares)			11,919,404
Warrants exercised (in shares)	(6,038,227)	(3,120,115)	(2,188,999)
Warrants expired (in shares)			(1,250)
Number of Warrants, Ending balance (in shares)	3,234,750	9,272,977	12,393,092
Weighted Average Exercise Price
Weighted Average Exercise Price, Beginning balance (in dollar per share)	$ 1.73	$ 1.31	$ 6.13
Weighted average exercise price, warrants granted (in dollar per share)			0.0001
Weighted average exercise price, warrants exercised (in dollar per share)	(0.06)	(0.08)	(0.002)
Weighted average exercise price, warrants expired (in dollar per share)			(31.17)
Weighted Average Exercise Price, Ending balance (in dollar per share)	$ 4.84	$ 1.73	$ 1.31

SHAREHOLDERS' EQUITY (Summary_4

SHAREHOLDERS' EQUITY (Summary of Warrants Outstanding) (Details) - $ / shares	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2018
Warrant outstanding and Exercise price
Number of Warrants	3,234,750	9,272,977	12,393,092	2,663,937
Exercise price (in dollars per share)	$ 4.84	$ 1.73	$ 1.31	$ 6.13
Warrants Exercise Price $66.00 [Member]
Warrant outstanding and Exercise price
Number of Warrants	227,273
Exercise price (in dollars per share)	$ 66
Expiry Date	Jan. 14, 2023
Warrants Exercise Price $42.80 [Member]
Warrant outstanding and Exercise price
Number of Warrants	7,477
Exercise price (in dollars per share)	$ 42.80
Expiry Date	Nov. 18, 2023
Warrants Exercise Price $4.00 [Member]
Warrant outstanding and Exercise price
Number of Warrants	80,000
Exercise price (in dollars per share)	$ 4
Expiry Date	Jan. 9, 2023
Warrants Exercise Price $0.0001 [Member]
Warrant outstanding and Exercise price
Number of Warrants	2,920,000
Exercise price (in dollars per share)	$ 0.0001
Expiry Date	Aug. 23, 2024

SUPPLEMENTAL DISCLOSURE WITH _2

SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS (Narrative) (Details) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2019
SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS
Number of shares issued upon cashless exercise of pre-funded warrants	81,303	1,652,530
Pre-funded warrants exercised	94,723	1,653,999
Transaction costs incurred through accounts payable and accrued liabilities		$ 64,804
Share issuance costs incurred through accounts payable and accrued liabilities		$ 303,951

RELATED PARTY TRANSACTIONS (Nar

RELATED PARTY TRANSACTIONS (Narrative) (Details) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Accounts Payable and Accrued Liabilities [Member]
Related Party Transaction [Line Items]
Due to related parties	$ 82,036	$ 87,846

INCOME TAXES (Reconciliation of

INCOME TAXES (Reconciliation of Income Taxes at Statutory Rates) (Details) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
INCOME TAXES
Loss for the year before income tax	$ (36,839,810)	$ (23,734,017)	$ (12,718,912)
Tax recovery at statutory income tax rates	(9,947,000)	(6,408,000)	(3,434,000)
Non-deductible share-based payments	1,575,000	2,031,000	227,000
Taxable capital gains			346,000
Other permanent differences including foreign exchange	(49,000)	21,000	3,000
Share issue costs	(2,492,000)	(849,000)	(720,000)
Change in statutory, foreign tax, foreign exchange rates and other	1,260,000	1,013,000	458,000
Adjustment to prior years provision versus statutory tax returns and expiry of non-capital losses	(725,000)	(307,000)	(196,000)
Change in valuation allowance	10,344,000	4,210,000	3,354,000
Total income tax expense	$ (34,349)	$ (288,647)	$ 37,920

INCOME TAXES (Significant Compo

INCOME TAXES (Significant Components of Future Tax Assets) (Details) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Deferred tax assets
Operating losses carried forward	$ 29,749,000	$ 21,297,000
Equipment and intangible assets	77,000	77,000
Investment tax credits	29,000	39,000
Financing costs	3,025,000	1,462,000
Federal R&D credit	210,000	0
Other	79,000	0
Gross future tax assets	33,169,000	22,875,000
Valuation allowance	(33,169,000)	(22,875,000)
Net future tax assets	$ 0	$ 0

INCOME TAXES (Narrative) (Detai

INCOME TAXES (Narrative) (Details) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
General corporate income tax rate	27.00%	27.00%	27.00%
Income tax (recovery) expense	$ (34,349)	$ (288,647)	$ 37,920
Canada
Non-capital loss carry-forwards	78,416,000	64,494,000
UNITED STATES | Us
Non-capital loss carry-forwards	$ 40,843,000	$ 20,249,000

SEGMENTED INFORMATION (Narrativ

SEGMENTED INFORMATION (Narrative) (Details)	12 Months Ended
	Sep. 30, 2021segment
SEGMENTED INFORMATION
Number of industries	1

FINANCIAL INSTRUMENTS AND RISK

FINANCIAL INSTRUMENTS AND RISK (Narrative) (Details) - 12 months ended Sep. 30, 2021	USD ($)	CAD ($)	USD ($)
Working Capital			$ 193,668,414
Cash, CDIC insured amount		$ 100,000
Cash, FDIC insured amount			$ 250,000
10% Change in Foreign Exchange Rate [Member]
Foreign currency risk, fluctuation in the net income (loss) reported due to change in exchange rate	$ 27,261

COMMITMENTS (Narrative) (Detail

COMMITMENTS (Narrative) (Details)	1 Months Ended	12 Months Ended
	Feb. 28, 2014USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2021CAD ($)	Sep. 30, 2020USD ($)
Grants Related to Androgen Receptor n-terminus Blocker Program for Prostate Cancer [Member]
Other Commitments [Line Items]
Total grant amount	$ 12,000,000
Grant Received Period	3 years
Final Payment of grant				$ 229,201
Threshold limit for aggregate royalty payments		$ 24,000,000
Grants Related to Androgen Receptor n-terminus Blocker Program for Prostate Cancer [Member] | Aggregate Royalty payment Up To $24,000,000
Other Commitments [Line Items]
Royalty percent revenue		4.00%	4.00%
Grants Related to Androgen Receptor n-terminus Blocker Program for Prostate Cancer [Member] | Aggregate Royalty payment After $24,000,000
Other Commitments [Line Items]
Royalty percent revenue		2.00%	2.00%
Texas | Grants Related to Androgen Receptor n-terminus Blocker Program for Prostate Cancer [Member]
Other Commitments [Line Items]
Grant requirement, number of years of operations in Texas		3 years	3 years
License Agreement [Member] | Technology-based intangible assets
Other Commitments [Line Items]
Minimum advance royalty payments			$ 85,000
Total amount of milestone payments after start of a Phase II clinical trial			50,000
Total amount of milestone payments after start of a Phase III clinical trial			900,000
Total amount of milestone payments at application for marketing approval			$ 1,450,000

COMMITMENTS (Schedule of Contra

COMMITMENTS (Schedule of Contractual Obligations) (Details) - Sep. 30, 2021	CAD ($)	USD ($)
Vendor Agreement [Member]
Other Commitments [Line Items]
2022	$ 25,000
2023	0
2024	0
2025	0
2026	0
Consulting Agreement [Member]
Other Commitments [Line Items]
2022		$ 35,000
2023		0
2024		0
2025		0
2026		0
Lease on US Office Spaces [Member]
Other Commitments [Line Items]
2022		113,288
2023		119,586
2024		81,509
2025		0
2026		$ 0
Royalty [Member] | License Agreement [Member]
Other Commitments [Line Items]
2022	85,000
2023	85,000
2024	85,000
2025	85,000
2026	$ 85,000